var title_f23_32_24064="Cholangiogram of hepaticojejunostomy";
var content_f23_32_24064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cholangiogram of hepaticojejunostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cholangiogram demonstrates bilateral hepaticojejunostomy anastomoses. There is opacification across the anastomoses and no evidence of leak.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24064=[""].join("\n");
var outline_f23_32_24064=null;
var title_f23_32_24065="Histoplasmosis spleen";
var content_f23_32_24065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histoplasmosis in the spleen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin and eosin-stained section of splenic tissue (x1000) obtained from a patient with overwhelming histoplasmosis, who presented with pneumonia. A macrophage in the center of the slide contains many yeast forms of Histoplasma capsulatum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24065=[""].join("\n");
var outline_f23_32_24065=null;
var title_f23_32_24066="Palatal erosion in reactive arthritis";
var content_f23_32_24066=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F83797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F83797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Palatal erosion in reactive arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sharply demarcated erosion of the hard palate is shown. This is among the more common of the oral manifestations of reactive arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2012 American College of Rheumatology. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24066=[""].join("\n");
var outline_f23_32_24066=null;
var title_f23_32_24067="Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)";
var content_f23_32_24067=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16922\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/47/25343\">",
"         Deep veins of the leg",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/60/24514\">",
"         Patient information: Factor V Leiden (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/11/14515\">",
"         Patient information: Latest medicines to prevent blood clots (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/42/27298\">",
"         Patient information: Staying healthy when you travel (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/44/2755\">",
"         Patient information: Warfarin (Coumadin) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/2/32803\">",
"         Patient information: What can go wrong after a heart attack? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/17/35091\">",
"         Patient information: Chronic venous disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/44/12998\">",
"         Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/29/2517\">",
"         Patient information: Pulmonary embolism (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/15/21747\">",
"         Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pulmonary-embolism-blood-clot-in-the-lungs-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H3650619\">",
"      <span class=\"h1\">",
"       What is a pulmonary embolism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A pulmonary embolism is a blockage in one of the blood vessels that supplies blood to the lungs. Most often these blockages are caused by blood clots that form elsewhere and then travel to the lungs. In rare cases, blockages can also be caused by air bubbles, tiny globs of fat, or pieces of tumor that travel to the lungs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1127786\">",
"      <span class=\"h1\">",
"       Why are blood clots dangerous?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If a blood clot forms or gets stuck inside a blood vessel, it can clog the vessel and keep blood from getting where it needs to go. When that happens in the lungs, the lungs can get damaged. Plus, having a blocked artery in the lung can make it hard to breathe or even lead to death.",
"     </p>",
"     <p>",
"      Most blood clots in the lungs actually form in the legs or pelvic area (where the legs branch from the body) and then travel to the lungs. Anyone who has had a blood clot in the lungs or who is at risk of one should know the symptoms of clots in these areas.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5823207\">",
"      <span class=\"h1\">",
"       What are the symptoms of blood clots in the lungs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Blood clots in the lungs can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Panting or trouble breathing",
"       </li>",
"       <li>",
"        Sharp, knife-like chest pain when you breathe in",
"       </li>",
"       <li>",
"        Coughing or coughing up blood",
"       </li>",
"       <li>",
"        A rapid heartbeat",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you get any of these symptoms, call 9-1-1. At the hospital, doctors can run tests to find out if you do have a clot. Blood clots in the lungs can lead to death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1127793\">",
"      <span class=\"h1\">",
"       What are the symptoms of blood clots in the legs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Blood clots in the legs cause different symptoms depending on whether the clots form in veins deep in the leg or in the veins near the surface of the skin.",
"     </p>",
"     <p>",
"      Blood clots in the",
"      <strong>",
"       deep veins",
"      </strong>",
"      of the legs are the most dangerous (",
"      <a class=\"graphic graphic_figure graphicRef70603 \" href=\"UTD.htm?24/47/25343\">",
"       figure 1",
"      </a>",
"      ). Clots in the deep veins can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Warmth and redness in the involved leg",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Blood clots in the veins near the surface of the skin can cause pain, redness, or infection. These clots sometimes also cause the veins to harden and bulge into ridges that look like cords. This is most common with the veins below the knee.",
"     </p>",
"     <p>",
"      If you think you have a blood clot in your leg, call your doctor or nurse right away. Blood clots in the veins near the surface of the skin are not usually dangerous. But blood clots in the deep veins of the leg can be serious and can travel to the lungs. Your doctor or nurse can run tests to find out if you do have a clot and where it is.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5823047\">",
"      <span class=\"h1\">",
"       Is there a test to find blood clots in the lungs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, there are several tests doctors can use to find out if a person has a blood clot in a lung. The most common tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        D-dimer blood test -- D-dimer is a substance in the blood that often goes up in people with a blood clot in a lung.",
"       </li>",
"       <li>",
"        CT pulmonary angiogram (also called a CT-PA) &ndash; A CT pulmonary angiogram is a special kind of X-ray that involves the use of computers. During this test, you have a dye injected into one of your veins. The dye shows up on X-rays and can show if any blood vessels are blocked.",
"       </li>",
"       <li>",
"        A",
"        <span class=\"nowrap\">",
"         ventilation/perfusion",
"        </span>",
"        lung scan (also called a",
"        <span class=\"nowrap\">",
"         V/Q",
"        </span>",
"        scan) &ndash; For this test, you inhale a small amount of a radioactive substance. You also have a radioactive dye injected into one of your veins. Then doctors look at how the different substances look on the scan. The image they see can show if one of the arteries in the lung is blocked.",
"       </li>",
"       <li>",
"        Pulmonary angiography &ndash; For this test, you have a small tube called a catheter inserted into one of the large veins in your body, usually one in your leg. Then doctors advance this tube up into the chest to where the major blood vessels of the lung are found. When the tube is in place, the doctors inject a dye that shows up on an X-ray.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1127807\">",
"      <span class=\"h1\">",
"       How are blood clots in the lungs treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Blood clots in the lungs are treated with medicines that dissolve clots or that keep clots from getting bigger. Some of these medicines are injected directly into a vein, while others come in shots or pills.",
"     </p>",
"     <p>",
"      If there is a reason that you cannot get one of these medicines, or the medicines cannot do enough to shrink or dissolve a clot, doctors can sometimes try another approach. They can do surgery to remove a clot from the lung or use a catheter like the one used for angiography to remove it.",
"     </p>",
"     <p>",
"      People who have had clots usually take a medicine called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      (brand name: Coumadin&reg;) for at least 3 months (and usually longer) after their clot is found. This medicine keeps the existing blood clot from getting bigger and also helps keep new blood clots from forming. It is important because people who have one clot often have another clot later on. Warfarin comes in a pill.",
"     </p>",
"     <p>",
"      If your doctor puts you on",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      , take it exactly as directed. If you forget or miss a dose, call your doctor to find out what to do. When you start taking it, you will need to have your blood tested often. That&rsquo;s because the effects of warfarin can change over time. Your blood needs to be checked to see how the drug is working. If there are changes, your doctor may need to adjust your dose. At the wrong doses, the drug can either stop working or lead to serious bleeding.",
"     </p>",
"     <p>",
"      Another treatment option that is appropriate only for some people is something called an &ldquo;inferior vena cava filter&rdquo; (also called an IVC filter). The inferior vena cava is the large vein that carries blood from your legs and the lower half of your body back up to your heart. Inferior vena cava filters go inside the inferior vena cava. They filter and trap any large clots that form below the location of the filter. Your doctor might suggest one of these filters for you if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You cannot safely take",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"         warfarin",
"        </a>",
"       </li>",
"       <li>",
"        You form clots even while on",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"         warfarin",
"        </a>",
"       </li>",
"       <li>",
"        You have a dangerous bleeding problem while on",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"         warfarin",
"        </a>",
"       </li>",
"       <li>",
"        You are so sick that another pulmonary embolism could kill you",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1127814\">",
"      <span class=\"h1\">",
"       Can I do anything on my own to prevent blood clots?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. People sometimes form clots because they have been sitting still for too long. People who travel on long airplane flights, for example, are at increased risk of blood clots. But you can prevent a clot during a long flight by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Standing up and walking around every hour or two",
"       </li>",
"       <li>",
"        Not smoking just before your trip",
"       </li>",
"       <li>",
"        Wearing loose, comfortable clothes",
"       </li>",
"       <li>",
"        Shifting your position while seated, and moving your legs and feet often",
"       </li>",
"       <li>",
"        Drinking plenty of fluids",
"       </li>",
"       <li>",
"        Wearing knee-high compression stockings",
"       </li>",
"       <li>",
"        Avoiding alcohol and medicines that make you sleepy, because they can impair your ability to move around",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1127821\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"       Patient information: Staying healthy when you travel (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=see_link\">",
"       Patient information: What can go wrong after a heart attack? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=see_link\">",
"       Patient information: Factor V Leiden (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/11/14515?source=see_link\">",
"       Patient information: Latest medicines to prevent blood clots (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/17/35091?source=see_link\">",
"       Patient information: Chronic venous disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"       Patient information: Pulmonary embolism (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/32/24067?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16922 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24067=[""].join("\n");
var outline_f23_32_24067=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3650619\">",
"      What is a pulmonary embolism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1127786\">",
"      Why are blood clots dangerous?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5823207\">",
"      What are the symptoms of blood clots in the lungs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1127793\">",
"      What are the symptoms of blood clots in the legs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5823047\">",
"      Is there a test to find blood clots in the lungs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1127807\">",
"      How are blood clots in the lungs treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1127814\">",
"      Can I do anything on my own to prevent blood clots?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1127821\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16922\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/47/25343\">",
"      Deep veins of the leg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/17/35091?source=related_link\">",
"      Patient information: Chronic venous disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=related_link\">",
"      Patient information: Factor V Leiden (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/11/14515?source=related_link\">",
"      Patient information: Latest medicines to prevent blood clots (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=related_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=related_link\">",
"      Patient information: What can go wrong after a heart attack? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_32_24068="Emergency contraception (morning after pill)";
var content_f23_32_24068=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/32/24068/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24068/contributors\" id=\"au7462\">",
"       Mimi Zieman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/32/24068/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24068/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/32/24068/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24068/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24068/contributors\" id=\"de2799\">",
"       Constanza Villalba, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?23/32/24068?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Women who forget to take their birth control pills, have a condom break during intercourse, or have unprotected sex for other reasons (including victims of sexual assault) now have a back-up method of protecting against pregnancy. This is called \"emergency contraception\" and goes by several other names, including \"postcoital contraception,\" \"the morning after pill,\" and \"Plan B,\" which is the brand name of one of the medications used for emergency contraception. Using emergency contraception should not be confused with taking medicine to induce an abortion, which is a very different medication and process.",
"    </p>",
"    <p>",
"     Emergency contraception is a method of birth control to be used",
"     <strong>",
"      occasionally",
"     </strong>",
"     , in specific emergency situations, not as a primary form of birth control. Other forms of birth control are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"      \"Patient information: Barrier methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=see_link\">",
"      \"Patient information: Permanent sterilization procedures for women (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/2/29730?source=see_link\">",
"      \"Patient information: Vasectomy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHEN TO USE EMERGENCY CONTRACEPTION",
"     </span>",
"    </p>",
"    <p>",
"     Any woman who has had unprotected sex for any reason can use emergency contraception. This includes women who have been raped. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/30/1509?source=see_link\">",
"      \"Patient information: Care after sexual assault (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Below are the different circumstances in which you might need emergency contraception:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If you had unprotected vaginal intercourse any time within the last five days (120 hours).",
"      </li>",
"      <li>",
"       If you used your regular method of birth control incorrectly (and had intercourse), or if your regular method of birth control might have failed (and you had intercourse) within the last five days (120 hours). Reasons why a regular method of birth control could fail include:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       A condom breaks, slips off, or is not used the whole time a couple is having sex",
"      </li>",
"      <li>",
"       A woman who normally takes birth control pills containing both estrogen and progestin forgets to take her birth control pills two days in a row",
"      </li>",
"      <li>",
"       A woman who normally takes birth control pills containing just progestin (called the \"minipill\") takes her pill more than three hours late",
"      </li>",
"      <li>",
"       A woman who normally uses injections of depot-medroxyprogesterone acetate (also called Depo-Provera&reg;; Depo-Provera&reg; Contraceptive; depo-subQ provera 104&trade;; and Provera&reg;) is more than two weeks late for her injection (some providers recommend emergency contraception if the woman is more than four weeks late for her injection)",
"      </li>",
"      <li>",
"       A diaphragm or cervical cap moves, breaks, tears, or is removed too soon",
"      </li>",
"      <li>",
"       A birth control skin patch comes off, is removed too early, or is put on too late",
"      </li>",
"      <li>",
"       A birth control vaginal ring comes out, is removed too early, or is inserted too late",
"      </li>",
"      <li>",
"       A man fails to \"pull out\" or withdraw in time and comes or ejaculates either inside the woman or on her genitals",
"      </li>",
"      <li>",
"       A sperm-killing tablet or film fails to melt before sexual intercourse",
"      </li>",
"      <li>",
"       A woman who uses the rhythm method makes a mistake figuring out the \"safe time\" in her cycle, or she has intercourse during the days she is likely to conceive",
"      </li>",
"      <li>",
"       An intrauterine device (IUD) accidentally comes out",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Is emergency contraception safe?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The pills used in hormonal emergency contraception contain the same hormones found in hormonal birth control methods (birth control pills, skin patches, vaginal rings, and one type of intrauterine contraceptive device). These hormones have been used safely for years.",
"    </p>",
"    <p>",
"     Even women who cannot use estrogen-containing hormonal birth control as their primary method of contraception (such as those with a history of heart attack, stroke, clotting disorders, migraine headaches, or liver disease, or who are breastfeeding) can use emergency contraception because the hormones are taken for only one day.",
"    </p>",
"    <p>",
"     Some types of emergency contraception do not contain any hormones. These types are the copper IUD and a new product, ulipristal acetate, which is sold under the brand names ella",
"     <sup>",
"      &reg;",
"     </sup>",
"     or ellaOne.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHERE TO GET EMERGENCY CONTRACEPTION",
"     </span>",
"    </p>",
"    <p>",
"     The US Food and Drug Administration has approved the over-the-counter sale of emergency contraception (levonorgestrel: Next Choice&reg;, Plan B&reg; One-Step) to men and women age 17 and older. If you are 17 or older and want to buy emergency contraception, you do not need a prescription.",
"    </p>",
"    <p>",
"     You should be able to get emergency contraception from almost any local pharmacy, as long as you have government-issued identification that proves you are at least 17 years old (for example, a driver's license). Adolescents age 16 and younger, on the other hand, need a prescription for emergency contraception.",
"    </p>",
"    <p>",
"     However, in some states pharmacists who have made special arrangements with a prescriber can legally dispense emergency contraception to women younger than 17 (information available online through",
"     <a class=\"external\" href=\"file://www.plannedparenthood.org/index.htm\">",
"      Planned Parenthood",
"     </a>",
"     and",
"     <a class=\"external\" href=\"file://ec.princeton.edu/\">",
"      file://ec.princeton.edu/",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Get it before you need it",
"     </span>",
"     &nbsp;&mdash;&nbsp;Even though emergency contraception is available without a prescription, it is not always easy to get to a pharmacy when you need to take the pills. As a result, healthcare providers recommend that women who are having sex get the pills needed for emergency contraception ahead of time, before they need them, and keep them at home. That's important because the pills are most effective when they are used shortly after unprotected sex.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      HOW EMERGENCY CONTRACEPTION WORKS",
"     </span>",
"    </p>",
"    <p>",
"     Researchers are not certain how emergency contraception works, but they do know that it probably works differently depending on where a woman is in her cycle. It also depends on the type of emergency contraception that she uses.",
"    </p>",
"    <p>",
"     However it works, one thing is clear: hormonal or intrauterine emergency contraception",
"     <strong>",
"      cannot",
"     </strong>",
"     reverse a pregnancy that has already happened. In other words, if a fertilized egg has already implanted itself in the uterus, hormonal emergency contraception will not interfere with the pregnancy or harm the baby. Hormonal or intrauterine emergency contraception is not the same as the \"abortion pill\", which contains very different medications. However, ulipristal acetate may interfere with a pregnancy that has started to develop in the uterus.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      HOW WELL DOES EMERGENCY CONTRACEPTION WORK?",
"     </span>",
"    </p>",
"    <p>",
"     The chances that a woman will get pregnant after unprotected sex vary depending on where she is in her cycle. For example, a woman in her mid-twenties who has sex one to two days",
"     <strong>",
"      before",
"     </strong>",
"     she ovulates, when she is most fertile, has about a one in three chance of getting pregnant. Meanwhile, a woman of the same age who has sex one to two days",
"     <strong>",
"      after",
"     </strong>",
"     she ovulates has a near zero chance of getting pregnant.",
"    </p>",
"    <p>",
"     In research studies of women given emergency contraception after unprotected sex any time during their cycle, the chance of pregnancy was less than one in 30 with the use of emergency contraception pills (",
"     <a class=\"graphic graphic_table graphicRef75095 \" href=\"UTD.htm?0/21/347\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      TYPES OF EMERGENCY CONTRACEPTION",
"     </span>",
"    </p>",
"    <p>",
"     There are two types of oral hormonal emergency contraception regimens:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       One regimen contains a form of the hormone progesterone (levonorgestrel)",
"      </li>",
"      <li>",
"       The other is a combination regimen containing forms of two hormones: progesterone and estrogen",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The levonorgestrel regimen is slightly more effective than the combination estrogen-progesterone pills, and less likely to cause nausea and vomiting, the most common side effect of pills used for emergency contraception (see",
"     <a class=\"local\" href=\"#H15\">",
"      'Side effects of emergency contraception'",
"     </a>",
"     below). Levonorgestrel is available in the United States under the product names Next Choice&reg;, and Plan B&reg; One-Step, which are available without a prescription for people age 17 and older.",
"    </p>",
"    <p>",
"     Even though levonorgestrel has advantages over estrogen-progesterone, some women find the combination regimen is easier to find. The combination estrogen-progesterone regimen is available by using many commonly prescribed birth control pills (",
"     <a class=\"graphic graphic_table graphicRef74604 \" href=\"UTD.htm?9/54/10093\">",
"      table 2",
"     </a>",
"     ). Birth control pills require a prescription.",
"    </p>",
"    <p>",
"     Ulipristal acetate (ella",
"     <sup>",
"      &reg;",
"     </sup>",
"     , ellaOne) is another form of oral emergency contraception. It is not a hormone. It works by preventing the hormone progesterone from having its normal effect on ovulation and the inside of the uterus.",
"    </p>",
"    <p>",
"     An intrauterine device (IUD) can also be used for emergency contraception. The copper IUD is a plastic and copper device that must be inserted into the uterus by a healthcare provider. It is much more effective at preventing pregnancy than the pill methods, but is less convenient, more costly in the short-term, and usually used by women who want to keep the IUD as an ongoing method of birth control. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     After unprotected sex, the chance of pregnancy is less than one in 500 in women who have a copper intrauterine device placed. (See",
"     <a class=\"local\" href=\"#H14\">",
"      'Copper IUD'",
"     </a>",
"     below.).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      HOW TO TAKE EMERGENCY CONTRACEPTION",
"     </span>",
"    </p>",
"    <p>",
"     You do not need to have a physical exam or any lab tests to take emergency contraception in pill form. However, if you need emergency contraception because you were raped, you should seek the help of a counselor or other healthcare professional. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/30/1509?source=see_link\">",
"      \"Patient information: Care after sexual assault (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Timing",
"     </span>",
"     &nbsp;&mdash;&nbsp;You can take emergency contraceptive pills any time during your menstrual cycle. It does not matter when you had your last period.",
"    </p>",
"    <p>",
"     Both the levonorgestrel pills and estrogen-progesterone pills are most effective when taken as soon as possible after unprotected sex. You can take them up to 120 hours (5 days) after sex, although the treatment become less effective as more time goes by.",
"    </p>",
"    <p>",
"     Ulipristal acetate is effective up to 120 hours (five days) after unprotected sex.",
"    </p>",
"    <p>",
"     The intrauterine device (IUD) can also be inserted up to 120 hours (five days) after unprotected sex.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Emergency contraception medication and dose",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Levonorgestrel",
"     </span>",
"     &nbsp;&mdash;&nbsp;Levonorgestrel is available in the United States as Next Choice&reg;, which contains two 0.75 mg tablets to be taken 12 hours apart. However, many healthcare providers suggest taking the two tablets together, rather than 12 hours apart, because it is more convenient, works as well as taking the two pills separately, and is not harmful. Alternately, you can take Plan B&reg; One-Step, which contains one 1.5 mg tablet that you take once.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H281158806\">",
"     <span class=\"h3\">",
"      Ulipristal acetate",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ulipristal acetate is available as ella",
"     <sup>",
"      &reg;",
"     </sup>",
"     or ellaOne, which consists of a single 30 mg tablet.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Estrogen-progesterone pills",
"     </span>",
"     &nbsp;&mdash;&nbsp;No estrogen-progesterone pill is available in pill packets specifically for emergency contraception. However many birth control pills contain these two hormones. The table provides information on which birth control pills you can take as emergency contraception, and how many pills to take for each dose (",
"     <a class=\"graphic graphic_table graphicRef74604 \" href=\"UTD.htm?9/54/10093\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Copper IUD",
"     </span>",
"     &nbsp;&mdash;&nbsp;The best way to prevent pregnancy is to have a copper IUD inserted. This makes the most sense if you would like to leave the IUD in place and use it as your ongoing method of birth control. Copper IUDs are discussed in detail separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Side effects of emergency contraception",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nausea and vomiting are the most common side effects of the emergency contraceptive pills. These side effects are more common with the combination regimen using pills that contain both estrogen and levonorgestrel than those that contain levonorgestrel alone. Emergency contraception is very safe, which is why it is now available without a prescription.",
"    </p>",
"    <p>",
"     The table shows the percentages of women who experience nausea and vomiting, depending on which type of emergency contraception they take (",
"     <a class=\"graphic graphic_table graphicRef77880 \" href=\"UTD.htm?0/26/427\">",
"      table 3",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Side effects for ulipristal acetate are similar to those for levonorgestrel.",
"    </p>",
"    <p>",
"     The copper IUD sometimes causes heavier periods. This often gets better with time.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Preventing nausea and vomiting",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you are worried about developing nausea and vomiting, you can take a medication to prevent these side effects.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Meclizine is a non-prescription medicine that helps prevent nausea and vomiting; it is sold under the brand names Antivert&reg;, Bonine&reg;, Dramamine&reg;, and Medi-Meclizine. It is important to follow the dosing instructions on the box or bottle.",
"      </li>",
"      <li>",
"       Metoclopramide (Reglan&reg;) is another medicine that helps prevent nausea and vomiting, but you'll need to get a prescription for it from your healthcare provider.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      What to do if you vomit",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you vomit within an hour after taking levonorgestrel pills, you should take medication for nausea and vomiting and then take then another full dose of levonorgestrel.",
"    </p>",
"    <p>",
"     If you vomit within an hour of taking levonorgestrel plus estradiol pills, you have two choices:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You can either take medication to prevent nausea and vomiting and take the full dose of levonorgestrel plus estradiol pills again; or",
"      </li>",
"      <li>",
"       You can switch to levonorgestrel pills in the hopes that they will not cause the same side effects as the combination pills.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      DO I NEED BIRTH CONTROL?",
"     </span>",
"    </p>",
"    <p>",
"     If you take emergency contraception, you will need to use some form of birth control until you get your period. You can still get pregnant if you have unprotected sex again after you take emergency contraception.",
"    </p>",
"    <p>",
"     If you normally use birth control pills, a patch, or a vaginal ring, but you missed some doses, you should resume those methods the day following your emergency contraception, but you will need to use a backup form of birth control (such as a condom) for at least seven days. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If you normally use condoms, a diaphragm, or a cervical cap, go back to using those methods right away. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"      \"Patient information: Barrier methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If you have unprotected sex again, you can take emergency contraception again.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHEN WILL I GET MY PERIOD?",
"     </span>",
"    </p>",
"    <p>",
"     Your period should come within a week of when it normally comes. Some women have their period a little sooner than expected; others have it a little later than expected. However, if you do not get your period within three or four weeks of taking emergency contraception, you should have a pregnancy test, either at home or in a medical office.",
"    </p>",
"    <p>",
"     If your pregnancy test is negative, wait for your menstrual period for one more week. If you still have not had a menstrual period by this time, call your doctor or nurse for further instructions.",
"    </p>",
"    <p>",
"     If you are using a hormonal method of birth control (pill, skin patch, vaginal ring, injection), be sure to take the next dose (or apply a new patch or insert a new ring) on schedule, even if you have not had your menstrual period. Call you healthcare provider for further instructions.",
"    </p>",
"    <p>",
"     In addition, call your doctor or nurse if you develop stomach pain or unexpected vaginal bleeding.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Emergency contraception is appropriate for any woman who has had recent unprotected sex for any reason. This includes women who have been raped, and women whose normal method of birth control may have failed.",
"      </li>",
"      <li>",
"       Women who can't take birth control pills for routine contraception because of medical conditions such as migraine or history of blood clots in the leg or lung can safely take emergency contraception.",
"      </li>",
"      <li>",
"       A woman does not need a physical exam or any lab tests to get emergency contraception.",
"      </li>",
"      <li>",
"       Women who need emergency contraception should take it as soon as possible after unprotected sex. Emergency contraception is most effective within the first day of unprotected sex, but it can work up to five days (120 hours) later. Women can take emergency contraception at any time during their menstrual cycle.",
"      </li>",
"      <li>",
"       Doctors recommend levonorgestrel pills rather than estradiol plus levonorgestrel pills because they are more effective and cause less nausea and vomiting. Doctors also recommend taking levonorgestrel as a single dose of 1.5 mg (2 pills at the same time) rather than as one dose of 0.75 mg followed by a second dose of 0.75 mg 12 hours later (even though that is what the label of Next Choice&reg; recommends). Plan B&reg; One-Step comes as a single 1.5 mg pill. Ulipristal acetate, where available, can be taken instead of levonorgestrel pills, and may be more effective than levonorgestrel pills for women 72 to 120 hours after unprotected intercourse.",
"      </li>",
"      <li>",
"       Women who use emergency contraception do not need to see a healthcare provider after taking it. However, they should have a pregnancy test if their period does not occur within three or four weeks, or if they develop unusual vaginal bleeding or abdominal pain.",
"      </li>",
"      <li>",
"       Women can still get pregnant if they have unprotected sexual intercourse again after taking emergency contraception pills. If necessary, they can repeat a course of emergency contraception, but a much more effective way to prevent pregnancy is to consistently use normal birth control methods.",
"      </li>",
"      <li>",
"       It's a good idea for women to have a supply of emergency contraction available at home \"just in case.\" Women age 16 and younger may want to get a prescription for emergency contraception before they need it.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413343134\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18218920\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/28/12738?source=see_link\">",
"      Patient information: Emergency contraception (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/4/28738?source=see_link\">",
"      Patient information: Care after rape or sexual assault (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18707?source=see_link\">",
"      Patient information: Hormonal birth control (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18218947\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"      Patient information: Barrier methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=see_link\">",
"      Patient information: Permanent sterilization procedures for women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/2/29730?source=see_link\">",
"      Patient information: Vasectomy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/30/1509?source=see_link\">",
"      Patient information: Care after sexual assault (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=see_link\">",
"      Contraception: Overview of issues specific to adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=see_link\">",
"      Emergency contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Child Health and Human Development (NICHD)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 370-2943",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nichd.nih.gov/\">",
"      www.nichd.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Women's Health Resource Center (NWHRC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (877) 986-9472",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.healthywomen.org/\">",
"      www.healthywomen.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Planned Parenthood Federation of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Phone: (212) 541-7800",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.plannedparenthood.org/\">",
"      www.plannedparenthood.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/\">",
"      www.hormone.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Emergency Contraception Website, Princeton University",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.not-2-late.com/\">",
"      www.not-2-late.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?23/32/24068/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?23/32/24068?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24068/abstract/1\">",
"      Polis CB, Schaffer K, Blanchard K, et al. Advance provision of emergency contraception for pregnancy prevention (full review). Cochrane Database Syst Rev 2007; :CD005497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24068/abstract/2\">",
"      Harper CC, Cheong M, Rocca CH, et al. The effect of increased access to emergency contraception among young adolescents. Obstet Gynecol 2005; 106:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24068/abstract/3\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists, Number 69, December 2005 (replaces Practice Bulletin Number 25, March 2001). Emergency contraception. Obstet Gynecol 2005; 106:1443.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f23_32_24068=[""].join("\n");
var outline_f23_32_24068=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHEN TO USE EMERGENCY CONTRACEPTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHERE TO GET EMERGENCY CONTRACEPTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           HOW EMERGENCY CONTRACEPTION WORKS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           HOW WELL DOES EMERGENCY CONTRACEPTION WORK?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           TYPES OF EMERGENCY CONTRACEPTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           HOW TO TAKE EMERGENCY CONTRACEPTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           DO I NEED BIRTH CONTROL?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHEN WILL I GET MY PERIOD?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?0/21/347\" title=\"table 1\">",
"           Pregnancy rate with emergency contraception",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?9/54/10093\" title=\"table 2\">",
"           Birth control pills used for emergency contraception",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?0/26/427\" title=\"table 3\">",
"           Risk of nausea and vomiting with emergency contraception",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f23_32_24069="Intercostal space";
var content_f23_32_24069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contents of typical intercostal space",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note order of structures in the costal groove from superior to inferior: VAN (vein, artery, and nerve).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore, KL and Agur, A. Essential Clinical Anatomy, 2nd Ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright &copy;2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24069=[""].join("\n");
var outline_f23_32_24069=null;
var title_f23_32_24070="Skull fracture CT scan";
var content_f23_32_24070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Skull fracture CT scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The axial image of the skull in the transverse plane&nbsp;using bone windows (A) is displayed alongside the 3D reconstructed view (B). A linear fracture of the right occipital bone (red arrow) is noted just to the right of midline. The 3D view shows the fracture extending from the right side of the lambdoid suture to the inferior margin of the right occipital bone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24070=[""].join("\n");
var outline_f23_32_24070=null;
var title_f23_32_24071="Treatment of nephrogenic diabetes insipidus";
var content_f23_32_24071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of nephrogenic diabetes insipidus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/32/24071/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24071/contributors\">",
"     Daniel G Bichet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/32/24071/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24071/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24071/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/32/24071/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24071/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/32/24071/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrogenic diabetes insipidus (DI) results from partial or complete resistance of the kidney to the effects of antidiuretic hormone. As a result, patients with this disorder are not likely to have a good response to hormone administration (as dDAVP) or to drugs that increase either the renal response to ADH or ADH secretion.",
"   </p>",
"   <p>",
"    Nephrogenic DI can be hereditary or acquired. In adults, a concentrating defect severe enough to produce polyuria due to nephrogenic DI is most often due to chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    use or hypercalcemia, and less frequently to other conditions that impair tubular function, such as Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/1\">",
"     1",
"    </a>",
"    ]. Release of ureteral obstruction is often associated with a diuresis, but this is short-lived and does not require specific therapy other than maintenance fluids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12050?source=see_link\">",
"     \"Urine output in urinary tract obstruction and postobstructive diuresis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary nephrogenic DI, which is largely an X-linked disease, may also be seen by internists since early recognition and treatment in infancy has led to survival to adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, affected women may be carriers with few or no symptoms until pregnancy or other stress.",
"   </p>",
"   <p>",
"    In infants with hereditary nephrogenic DI, treatment is aimed at minimizing the polyuria and avoiding hypernatremia and volume depletion. In adults, therapy is usually aimed at correcting the underlying disorder or discontinuing an offending drug. In hypercalcemic patients, for example, normalization of the plasma calcium concentration usually leads to amelioration of polyuria. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -induced nephrogenic DI may be irreversible if the patient already has severe tubular injury and a marked concentrating defect [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=see_link\">",
"     \"Renal toxicity of lithium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the treatment of polyuria in patients with nephrogenic DI will be reviewed here. The causes of nephrogenic DI, the diagnostic approach to polyuria, and the treatment of central diabetes insipidus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine output in patients with nephrogenic DI can be lowered with a low salt, low protein diet, diuretics, and nonsteroidal antiinflammatory drugs (NSAIDs). In infants, early recognition is of immediate clinical significance because treatment can avert the physical and mental retardation that results from repeated episodes of dehydration and hypernatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, the decision to undertake treatment must be based upon the individual patient's intolerance of the polyuria and polydipsia since, in almost all patients, the thirst mechanism is sufficient to maintain the plasma sodium in the high-normal range. The treatment of patients with hypernatremia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link\">",
"     \"Treatment of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Special considerations in hereditary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given their inability to independently respond to increased thirst, infants and very young children should be offered water every two hours during the day and night. In severe cases, continuous gastric feeding may be required. However, the ingestion of large quantities of water may exacerbate physiologic gastroesophageal reflux in infants and toddlers, which may require treatment. Appetite and growth should be monitored closely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The high urine flow associated with hereditary nephrogenic DI induces dilatation of the urinary tract (hydronephrosis) and bladder in &ge;50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. A rare complication is progressive loss of renal function and possible end-stage renal disease, probably related to voluntary retention of urine leading to bladder dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. These problems may also occur with other causes of massive urine volumes, most commonly seen with primary polydipsia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreasing urine flow with the interventions discussed below, and frequent voiding and \"double voiding\" (to empty the bladder entirely) are important preventive measures. This approach should be taught to children once they are old enough, and should be continued in adulthood, to prevent severe dilatation of the urinary tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Decreased dietary solute",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the urine osmolality is fixed, as in nephrogenic DI, the urine output is determined by solute excretion. Suppose that the maximum urine osmolality is 150",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    In this setting, the daily urine volume will be 5 liters if solute excretion is in the normal range at 750",
"    <span class=\"nowrap\">",
"     mosmol/day,",
"    </span>",
"    but only 3 liters if solute excretion is lowered to 450",
"    <span class=\"nowrap\">",
"     mosmol/day",
"    </span>",
"    by dietary modification.",
"   </p>",
"   <p>",
"    These observations provide the rationale for the use of a low salt, low protein diet to diminish the urine output in nephrogenic DI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. The reduction in urine output will be directly proportional to the decrease in solute intake and excretion. Restriction of salt intake to &le;100",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    (2.3 g sodium) and protein intake to &le;1.0",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    may be reasonable goals, but such diets are not easy to achieve and maintain. Furthermore, protein restriction in infants and young children may be harmful and is not advised. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"     \"Patient information: Low sodium diet (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most children with nephrogenic DI are underweight and relatively short during the first years of life, their height and weight become progressively normal during school-age years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/11\">",
"     11",
"    </a>",
"    ]. These growth observations could be related in part to limited caloric intake and decreased dietary solute during the first years of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazide diuretics in combination with a low solute diet can diminish the degree of polyuria in patients with nephrogenic DI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/1,12-14\">",
"     1,12-14",
"    </a>",
"    ]. The potassium-sparing diuretic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    also may be helpful, both by its additive effect with the thiazide diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/15\">",
"     15",
"    </a>",
"    ] and, with reversible",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -induced disease, by possibly allowing lithium to be continued (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A thiazide diuretic (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , 25 mg once or twice daily) acts by inducing mild volume depletion. As little as a 1 to 1.5 kg weight loss can reduce the urine output by more than 50 percent (eg, from 10",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    to below 3.5",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    in a study of patients with nephrogenic DI on a severely sodium-restricted diet [9",
"    <span class=\"nowrap\">",
"     meq/day])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This effect is presumably mediated by a hypovolemia-induced increase in proximal sodium and water reabsorption, thereby diminishing water delivery to the ADH-sensitive sites in the collecting tubules and reducing the urine output. Diuretic therapy can lead to a variety of usually mild electrolyte complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=see_link\">",
"     \"Time course of loop and thiazide diuretic-induced electrolyte complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H27627359#H27627359\">",
"     \"Causes of hypokalemia\", section on 'Diuretics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=see_link\">",
"     \"Diuretic-induced hyperuricemia and gout\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The initial natriuresis and therefore the later antipolyuric response can be enhanced by combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    (or other potassium-sparing diuretic) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/16\">",
"     16",
"    </a>",
"    ]. This regimen has an additional benefit, since amiloride partially blocks the potassium wasting induced by the thiazide.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     Amiloride",
"    </a>",
"    may be particularly beneficial in patients with reversible",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    nephrotoxicity, given its site and mechanism of action [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. If amiloride is used, a small contraction of extracellular fluid volume may ensue, and it may be necessary to decrease the dose of lithium chronically administered and to measure plasma concentrations at frequent intervals until a new steady state is achieved. This drug closes the sodium channels in the luminal membrane of the collecting tubule cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/19\">",
"     19",
"    </a>",
"    ]. These channels constitute the mechanism by which filtered lithium normally enters these cells and then interferes with their response to ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/15\">",
"     15",
"    </a>",
"    ]. The permeability for lithium of the epithelial sodium channel (ENaC) is 1.5- to twofold higher than that for sodium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/20\">",
"     20",
"    </a>",
"    ]. Whereas sodium is extruded from the interior of the cell to the blood compartment by the sodium pump (Na-K-ATPase) located at the basolateral membrane, lithium is a poor substrate for the sodium pump. As a consequence, toxic intracellular levels could build up quickly in all cells expressing ENaC at their plasma membrane and exposed to therapeutic concentrations of lithium (0.6 to 1.2",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=see_link\">",
"     \"Renal toxicity of lithium\"",
"    </a>",
"    .) Glycogen synthase kinase 3 (GSK-3 beta) is inhibited by lithium and is probably the common molecular target for the primary and secondary toxic effects of lithium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A loop diuretic, although also capable of inducing mild volume depletion, is not as likely to lower the urine output in nephrogenic DI. These agents decrease sodium chloride reabsorption in the medullary thick ascending limb of the loop of Henle, thereby decreasing the accumulation of NaCl in the medullary interstitium that is essential for the production of a concentrated urine. Thus, a loop diuretic induces relative ADH resistance, an effect that is counterproductive in nephrogenic DI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of NSAIDs in this setting is dependent upon inhibition of renal prostaglandin synthesis. In normal subjects, prostaglandins antagonize the action of ADH and NSAIDs increase concentrating ability [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. If, for example, normal subjects are given a submaximal dose of ADH, the ensuing rise in urine osmolality can be increased by more than 200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    if the patient has been pretreated with a NSAID [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/22\">",
"     22",
"    </a>",
"    ]. The net effect in patients with DI may be a 25 to 50 percent reduction in urine output [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/13,14,24\">",
"     13,14,24",
"    </a>",
"    ], a response that is partially additive to that of a thiazide diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/14,16\">",
"     14,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach is particularly beneficial in patients with polyuria due to complex congenital polyuric-polydipsic Bartter-like syndromes, in whom prostaglandins appear to be pathogenetically important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link&amp;anchor=H3869754#H3869754\">",
"     \"Bartter and Gitelman syndromes\", section on 'Role of prostaglandins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not all NSAIDs are equally effective in a given patient; as an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    appears to have a greater effect than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/13\">",
"     13",
"    </a>",
"    ]. A variety of complications may ensue with long-term use of NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Exogenous ADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with",
"    <strong>",
"     non-hereditary",
"    </strong>",
"    nephrogenic DI have partial rather than complete resistance to ADH. It is therefore possible that attaining supraphysiologic hormone levels will increase the renal effect of ADH to a clinically important degree. In some patients with nephrogenic DI, exogenous ADH has been found to increase the urine osmolality by 40 to 45 percent, an effect that would be expected to produce a similar decline in urine volume [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/17,25,26\">",
"     17,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP) may be tried in patients who have persistent symptomatic polyuria after implementation of the above regimen. One case report of a patient with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -induced nephrogenic DI suggested that benefit may be more likely if desmopressin is combined with a NSAID [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Experimental approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with congenital X-linked nephrogenic DI have defective V2 vasopressin receptors that are unable to properly fold intracellularly and, as a consequence, do not transfer to the cell surface where the receptors could respond to circulating vasopressin. Several new approaches to treatment of this disorder are being investigated: V2 receptor chaperones and V2 receptor bypass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Vasopressin V2 receptor gene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6612734\">",
"    <span class=\"h3\">",
"     V2 receptor chaperones",
"    </span>",
"    &nbsp;&mdash;&nbsp;In in vitro systems, the administration of selective, cell permeable nonpeptide V2 and V1a receptor antagonists were able to rescue mutant V2 receptors, presumably acting intracellularly to promote proper folding and maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This resulted in the expression of functional cell surface V2 receptors, suggesting that such a therapeutic approach may be effective in patients.",
"   </p>",
"   <p>",
"    In a pilot study, a nonpeptide V1a receptor antagonist was administered to five men with nephrogenic DI (each with one of three identified mutations in the AVPR2 gene that codes for the V2 receptor) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/29\">",
"     29",
"    </a>",
"    ]. This resulted in an increase in urine osmolality from a mean of 100 to 150",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    and reductions in urine volume from 12 to 8",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    and in water intake from 11 to 7",
"    <span class=\"nowrap\">",
"     L/day.",
"    </span>",
"    Nonpeptide V2 agonists have also been demonstrated experimentally to rescue misfolded AVPR2 mutations responsible for X-linked nephrogenic DI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most mutations in aquaporin-2 (the vasopressin-sensitive water channel) that are associated with nephrogenic DI result in proteins being retained in the intracellular space [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/32\">",
"     32",
"    </a>",
"    ]. Research to find chaperone-like molecules to help direct these proteins to the cell surface is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6612741\">",
"    <span class=\"h3\">",
"     V2 receptor bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antidiuretic activity of the V2 receptor is mediated by the activation of a G protein signaling cascade that leads to increased",
"    <strong>",
"    </strong>",
"    intracellular cyclic AMP and the trafficking of aquaporin-2 to the cell membrane. The collecting duct also expresses two prostaglandin E2 receptors (EP2 and EP4) that, similar to the V2 receptor signalling cascade, can increase intracellular cyclic AMP; prostaglandin E2 signalling through these receptors increases the apical membrane abundance and phosphorylation of aquaporin-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, stimulation of prostaglandin E2 receptors EP2 and EP4 may be a way of bypassing the need for V2 receptor signalling. In a mouse model of X-linked nephrogenic DI, for example, ONO-AE1-329, a selective agonist of the EP4 prostaglandin E2 receptor in the collecting tubule cells, increased urine osmolality from 150 to 500",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    H2O [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/55/43889?source=see_link\">",
"       \"Patient information: Diabetes insipidus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrogenic DI results from partial or complete resistance of the kidney to the effects of antidiuretic hormone. In adults, a concentrating defect severe enough to produce polyuria due to nephrogenic DI is most often due to chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    use or hypercalcemia, and less frequently to other conditions that impair tubular function, such as Sj&ouml;gren's syndrome. In infants, congenital nephrogenic DI is most common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a cause can be identified, we recommend correcting the underlying disorder (eg, hypercalcemia) or discontinuing the offending drug, if feasible.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    -induced nephrogenic DI may be irreversible if tubular injury is severe, and there is a marked concentrating defect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=see_link\">",
"     \"Renal toxicity of lithium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are usually no adverse medical effects of polyuria although, as noted above, the functional hydronephrosis in congenital nephrogenic DI rarely leads to significant renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24071/abstract/7\">",
"     7",
"    </a>",
"    ]. As a result, the only indication for therapy in adults is to relieve the patient's symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of the polyuria in nephrogenic DI consists of the following sequential approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All adult patients should be instructed to take a low sodium-low protein diet as tolerated, and all infants and young children should be provided a low sodium diet. The reduction in urine output will be directly proportional to the fall in solute excretion. As a result, the efficacy of solute restriction will depend directly upon patient compliance. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Decreased dietary solute'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all patients who have significant polyuria, we recommend frequent and \"double-voiding\" to avoid bladder dilatation and dysfunction.",
"     </li>",
"     <li>",
"      In all children, and in adults with symptomatic polyuria persisting despite a low solute diet, we recommend starting a thiazide diuretic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      25 mg once daily to a usual maximum of 25 mg twice daily in adults, and appropriate dosing in children) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The preferred initial therapy is different in children with polyuria due to complex congenital polyuric-polydipsic Bartter-like syndromes, in whom we recommend NSAIDs (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nonsteroidal antiinflammatory drugs'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link&amp;anchor=H3869775#H3869775\">",
"       \"Bartter and Gitelman syndromes\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      if the urine output is insufficiently reduced (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We recommend amiloride as part of primary therapy to prevent progression of, or possibly improve,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      -induced DI in patients in whom lithium is continued (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , a low sodium diet and the use of thiazide",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    may increase the plasma level of lithium. Thus, frequent measurements of lithium and a decrease in the daily lithium dosage may be necessary when initiating such treatments.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If symptomatic polyuria persists, we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      if there are no contraindications (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nonsteroidal antiinflammatory drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who cannot be treated with NSAIDs or who have persistent symptomatic polyuria after the addition of NSAIDs, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Exogenous ADH'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hereditary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are special considerations in the management of hereditary nephrogenic DI, particularly in infants and young children. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Special considerations in hereditary disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants and very young children, we recommend offering water every two hours, with the goal of avoiding severe dehydration and hypernatremia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If gastroesophageal reflux becomes problematic, we recommend appropriate management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link\">",
"       \"Management of gastroesophageal reflux disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In all children, we recommend implementation of measures to decrease urine flow as discussed above, and frequent and \"double voiding,\" with the goal of avoiding dilatation of the urinary tract and bladder (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest continuing these preventive measures to avoid dilatation of the urinary tract in adulthood.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 754-759,782-783.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/2\">",
"      Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 2005; 16:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/3\">",
"      Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987; 10:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/4\">",
"      Ulinski T, Grapin C, Forin V, et al. Severe bladder dysfunction in a family with ADH receptor gene mutation responsible for X-linked nephrogenic diabetes insipidus. Nephrol Dial Transplant 2004; 19:2928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/5\">",
"      Shalev H, Romanovsky I, Knoers NV, et al. Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus. Nephrol Dial Transplant 2004; 19:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/6\">",
"      Uribarri J, Kaskas M. Hereditary nephrogenic diabetes insipidus and bilateral nonobstructive hydronephrosis. Nephron 1993; 65:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/7\">",
"      Streitz JM Jr, Streitz JM. Polyuric urinary tract dilatation with renal damage. J Urol 1988; 139:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/8\">",
"      Zender HO, Ruedin P, Moser F, et al. Traumatic rupture of the urinary tract in a patient presenting nephrogenic diabetes insipidus associated with hydronephrosis and chronic renal failure: case report and review of the literature. Clin Nephrol 1992; 38:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/9\">",
"      Higuchi A, Kawamura T, Nakai H, Hasegawa Y. Infrequent voiding in nephrogenic diabetes insipidus as a cause of renal failure. Pediatr Int 2002; 44:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/10\">",
"      Wesche D, Deen PM, Knoers NV. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol 2012; 27:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/11\">",
"      van Lieburg AF, Knoers NV, Monnens LA. Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1999; 10:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/12\">",
"      Earley LE, Orloff J. THE MECHANISM OF ANTIDIURESIS ASSOCIATED WITH THE ADMINISTRATION OF HYDROCHLOROTHIAZIDE TO PATIENTS WITH VASOPRESSIN-RESISTANT DIABETES INSIPIDUS. J Clin Invest 1962; 41:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/13\">",
"      Libber S, Harrison H, Spector D. Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors. J Pediatr 1986; 108:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/14\">",
"      Monnens L, Jonkman A, Thomas C. Response to indomethacin and hydrochlorothiazide in nephrogenic diabetes insipidus. Clin Sci (Lond) 1984; 66:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/15\">",
"      Batlle DC, von Riotte AB, Gaviria M, Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 1985; 312:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/16\">",
"      Knoers N, Monnens LA. Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothiazide in the treatment of nephrogenic diabetes insipidus. J Pediatr 1990; 117:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/17\">",
"      Bedford JJ, Weggery S, Ellis G, et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol 2008; 3:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/18\">",
"      Christensen BM, Zuber AM, Loffing J, et al. alphaENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus. J Am Soc Nephrol 2011; 22:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/19\">",
"      Kortenoeven ML, Li Y, Shaw S, et al. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int 2009; 76:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/20\">",
"      Gr&uuml;nfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/21\">",
"      O'Brien WT, Harper AD, Jov&eacute; F, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004; 24:6791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/22\">",
"      Berl T, Raz A, Wald H, et al. Prostaglandin synthesis inhibition and the action of vasopressin: studies in man and rat. Am J Physiol 1977; 232:F529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/23\">",
"      Stokes JB. Integrated actions of renal medullary prostaglandins in the control of water excretion. Am J Physiol 1981; 240:F471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/24\">",
"      Allen HM, Jackson RL, Winchester MD, et al. Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Intern Med 1989; 149:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/25\">",
"      Miller M, Dalakos T, Moses AM, et al. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med 1970; 73:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/26\">",
"      Zerbe RL, Robertson GL. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N Engl J Med 1981; 305:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/27\">",
"      Stasior DS, Kikeri D, Duel B, Seifter JL. Nephrogenic diabetes insipidus responsive to indomethacin plus dDAVP. N Engl J Med 1991; 324:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/28\">",
"      Morello JP, Salahpour A, Laperri&egrave;re A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000; 105:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/29\">",
"      Bernier V, Morello JP, Zarruk A, et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2006; 17:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/30\">",
"      Robben JH, Kortenoeven ML, Sze M, et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci U S A 2009; 106:12195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/31\">",
"      Jean-Alphonse F, Perkovska S, Frantz MC, et al. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 2009; 20:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/32\">",
"      Sasaki S. Nephrogenic diabetes insipidus: update of genetic and clinical aspects. Nephrol Dial Transplant 2004; 19:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/33\">",
"      Yang B, Zhao D, Verkman AS. Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation. FASEB J 2009; 23:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24071/abstract/34\">",
"      Olesen ET, R&uuml;tzler MR, Moeller HB, et al. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A 2011; 108:12949.",
"     </a>",
"    </li>",
"    <li>",
"     Li, JH, Chou, CL, Li, B, et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J Clin Invest. 2009 Sep 1 [Epub ahead of print].",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2382 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24071=[""].join("\n");
var outline_f23_32_24071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Special considerations in hereditary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Decreased dietary solute",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Exogenous ADH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Experimental approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6612734\">",
"      - V2 receptor chaperones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6612741\">",
"      - V2 receptor bypass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hereditary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=related_link\">",
"      Diuretic-induced hyperuricemia and gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/55/43889?source=related_link\">",
"      Patient information: Diabetes insipidus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=related_link\">",
"      Time course of loop and thiazide diuretic-induced electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=related_link\">",
"      Treatment of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12050?source=related_link\">",
"      Urine output in urinary tract obstruction and postobstructive diuresis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_32_24072="Renal and urinary tract physiology in normal pregnancy";
var content_f23_32_24072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal and urinary tract physiology in normal pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/32/24072/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24072/contributors\">",
"     Ravi I Thadhani, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24072/contributors\">",
"     Sharon E Maynard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/32/24072/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24072/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24072/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/32/24072/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24072/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/32/24072/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal pregnancy is characterized by profound changes in almost every organ system in order to accommodate the demands of the fetoplacental unit. This topic will review changes in the lower urinary tract and kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     URINARY TRACT CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy affects both the kidney and the remainder of the urinary tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Increased renal size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both kidneys increase in size by 1 to 1.5 cm during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/1\">",
"     1",
"    </a>",
"    ]. Kidney volume increases by up to 30 percent, primarily due to an increase in renal vascular and interstitial volume. There are no histological changes or changes in number of nephrons, but the glomerular filtration rate is also increased (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Increase in GFR'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The renal pelvises and caliceal systems may be dilated as a result of progesterone effects and mechanical compression of the ureters at the pelvic brim (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Ureters'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ureters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilatation of the ureters and renal pelvis (hydroureter and hydronephrosis) is more prominent on the right than the left and is seen in up to 80 percent of pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/2\">",
"     2",
"    </a>",
"    ]. These changes can be visualized on ultrasound examination by the second trimester, and may not resolve until 6 to 12 weeks postpartum.",
"   </p>",
"   <p>",
"    The dilated collecting system can hold 200 to 300 mL of urine. The resulting urinary stasis can serve as a reservoir for bacteria, which may contribute to the increased risk of pyelonephritis in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=see_link\">",
"     \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hydroureter and hydronephrosis in pregnancy have been attributed to hormonal effects, external compression, and intrinsic changes in the ureteral wall [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/3\">",
"     3",
"    </a>",
"    ]. The following factors may contribute:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High concentrations of progesterone reduce ureteral tone, peristalsis, and contraction pressure.",
"     </li>",
"     <li>",
"      More prominent involvement of the right ureter may be due to dextrorotation of the uterus by the sigmoid colon, kinking of the ureter as it crosses the right iliac artery,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proximity to the right ovarian vein.",
"     </li>",
"     <li>",
"      The vessels in the suspensory ligament of the ovary enlarge and may compress the ureter at the brim of the bony pelvis.",
"     </li>",
"     <li>",
"      Uterine enlargement may cause the ureters to become elongated, tortuous, and displaced laterally as pregnancy advances. In rare cases, compression of the ureters causes pain and true urinary obstruction, which resolves with placing the mother on her side, insertion of stents,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=see_link&amp;anchor=H9#H9\">",
"       \"Acute kidney injury (acute renal failure) in pregnancy\", section on 'Urinary tract obstruction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertrophy of Waldeyer's sheath (the connective tissue that surrounds the ureters within the true pelvis) may prevent hormone-induced dilatation below the pelvic brim [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pathologic obstruction (ie, by nephrolithiasis or stricture) will also lead to ureteral dilatation. It frequently results in flank pain, and can often be distinguished from physiologic hydronephrosis by radiographically or sonographically visualizing the cause of the obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38340?source=see_link\">",
"     \"Nephrolithiasis during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bladder mucosa is edematous and hyperemic in pregnancy. Although progesterone-induced bladder wall relaxation may lead to increased capacity, the enlarging uterus displaces the bladder superiorly and anteriorly, and flattens it, which can decrease capacity. Studies of bladder capacity during pregnancy have yielded conflicting results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vesicoureteral reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder flaccidity may cause incompetence of the vesicoureteral valve. This change, combined with increased intravesical and decreased intraureteral pressure, appears to result in intermittent vesicoureteral reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     URINARY SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary frequency, nocturia, dysuria, urgency, and stress incontinence are common during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Frequency and nocturia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary frequency (voiding &gt;7 times per day) and nocturia (voiding &ge;2 times at night) are among the most common pregnancy-related complaints, affecting 80 to 95 percent of women at some point during gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Frequency appears to be multifactorial which is in part due to changes in bladder function and in part to a small increase in urine output (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Polyuria and diabetes insipidus'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. Urinary frequency typically begins in the first trimester; thus, mechanical compression of the bladder by the enlarged uterus is not likely to be the primary cause.",
"   </p>",
"   <p>",
"    Nocturia is common and increases with advancing gestation. In a survey of 256 pregnant women, 86 percent reported nocturia by the third trimester, with 20 percent of women indicating they voided three or more times nightly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/13\">",
"     13",
"    </a>",
"    ]. The major cause of nocturia appears to be that pregnant women excrete larger amounts of sodium and water during the night than nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/14\">",
"     14",
"    </a>",
"    ]. In the latter stages of pregnancy, this may be partially attributable to nocturnal mobilization of dependent edema in the lateral position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Urgency and incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have described an increase in urgency and urinary incontinence during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/12,15,16\">",
"     12,15,16",
"    </a>",
"    ], which may be due to uterine pressure on the bladder, hormonal effects on the suspensory ligaments of the urethra,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    altered neuromuscular function of the urethral striated sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/8,12,17,18\">",
"     8,12,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary incontinence during pregnancy is associated with an increased risk of persistent incontinence six months postpartum. Pregnancy- and delivery-related urinary incontinence is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Postpartum changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bladder and urethra inevitably experience some trauma during labor and delivery. The traumatic changes include mucosal congestion and submucosal hemorrhage, which are most evident at the trigone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bladder",
"    <span class=\"nowrap\">",
"     sensitivity/sensation",
"    </span>",
"    is also decreased from trauma. As a result, detrusor atony, increased postvoid residual urine, bladder overdistention, and urinary retention are frequently encountered in women in the first few days after delivery. These symptoms are typically mild, transient, and completely reversible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RENAL HEMODYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal pregnancy is characterized by widespread vasodilation, with increased arterial compliance and decreased systemic vascular resistance (",
"    <a class=\"graphic graphic_figure graphicRef54685 \" href=\"UTD.htm?36/59/37821\">",
"     figure 1",
"    </a>",
"    ). These global hemodynamic changes are accompanied by increases in renal perfusion and glomerular filtration rate (",
"    <a class=\"graphic graphic_table graphicRef66445 \" href=\"UTD.htm?6/12/6347\">",
"     table 1",
"    </a>",
"    ). In late gestation, assumption of the left lateral position is associated with increases in glomerular filtration rate and sodium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Humoral factors that contribute to volume regulation during pregnancy and cardiovascular and hemodynamic changes related to pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13274?source=see_link\">",
"     \"Maternal endocrine and metabolic adaptation to pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Increase in GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular filtration rate (GFR) rises markedly during pregnancy, primarily due to elevations in cardiac output and renal blood flow. Studies in both rodents and humans suggest that the increase in GFR results from enhanced glomerular plasma flow, rather than increased intraglomerular capillary pressure.",
"   </p>",
"   <p>",
"    The increase in GFR is observed within one month of conception and peaks at approximately 40 to 50 percent above baseline levels by the early second trimester and then declines slightly toward term [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/21\">",
"     21",
"    </a>",
"    ]. Renal blood flow increases by 80 percent above nonpregnant levels.",
"   </p>",
"   <p>",
"    The physiologic increase in GFR during pregnancy results in a decrease in serum creatinine concentration, which falls by an average of 0.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (35",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    to a normal range of 0.4 to 0.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (35 to 70",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Thus, a serum creatinine of 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (88",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    while normal in a non-pregnant individual, reflects renal impairment in a pregnant woman. Blood urea nitrogen (BUN) levels fall to approximately 8 to 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.9 to 3.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for the same reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms for decreased vascular resistance and increased renal plasma flow during pregnancy are not fully understood. Reduced vascular responsiveness to vasopressors such as angiotensin 2, norepinephrine, and vasopressin is well-documented [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/22\">",
"     22",
"    </a>",
"    ]. Nitric oxide synthesis increases during normal pregnancy and may contribute to the systemic and renal vasodilation and the fall in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ovarian hormone and vasodilator relaxin appears to be a key upstream mediator of enhanced nitric oxide signaling in pregnancy. Relaxin is a peptide hormone in the insulin family; it is normally produced in the corpus luteum, and in pregnancy is secreted in large amounts by the placenta and decidua in response to human chorionic gonadotropin (hCG) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/25\">",
"     25",
"    </a>",
"    ]. Relaxin increases endothelin and nitric oxide production in the renal circulation, leading to generalized renal vasodilation, decreased renal afferent and efferent arteriolar resistance, and a subsequent increase in renal blood flow and GFR.",
"   </p>",
"   <p>",
"    Chronic administration of relaxin to conscious male and castrated female rats mimics the renal hemodynamic changes of pregnancy (20 to 40 percent increase in GFR and renal plasma flow); these changes can be abolished by the administration of a nitric oxide synthase inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/26\">",
"     26",
"    </a>",
"    ]. In pregnant rats, increases in GFR and renal plasma flow can also be abolished by the administration of antirelaxin antibodies or by ovariectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Estimation of GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of pregnant women with preeclampsia or preexisting kidney disease requires an understanding of whether the GFR (and therefore, disease severity) is changing or stable; knowledge of the absolute value of the GFR is not usually needed. Changes in GFR are best identified by monitoring changes in the serum creatinine concentration. A rising serum creatinine concentration implies a reduction in GFR, a falling level indicates improvement, and a stable value usually reflects stable function. Among women with a normal or near normal serum creatinine at baseline, a small rise in serum creatinine can reflect a marked reduction in GFR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of renal function with a 24-hour urine collection for creatinine clearance is cumbersome for the patient, and is of limited accuracy in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/28\">",
"     28",
"    </a>",
"    ]. Overcollection and undercollection of 24-hour urine samples appear to be more common in pregnancy than in nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/28\">",
"     28",
"    </a>",
"    ]. This may be due, in part, to urinary stasis from dilatation of the lower urinary tract in pregnancy; several hundred milliliters of urine can be trapped in the dilated ureters, resulting in a significant lapse between urine formation and urine collection. Estimates of GFR based on the Modification of Diet in Renal Disease (MDRD) equation are also inaccurate during pregnancy; studies of GFR with measured values obtained by inulin clearance in early and late normal pregnancy and in pregnancies complicated by renal disease or preeclampsia show that MDRD substantially underestimates GFR during pregnancy and cannot be recommended for use in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20663247#H20663247\">",
"     \"Assessment of kidney function\", section on 'Limitations of using creatinine clearance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHER CHANGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mild hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma osmolality in normal pregnancy falls to a new set point of about 270",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    with a proportional decrease in plasma sodium concentration that is 4 to 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    below nonpregnancy levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/31\">",
"     31",
"    </a>",
"    ]. The physiological responses to changes in osmolality above or below the new set point (ie, thirst and release of antidiuretic hormone [ADH] from the pituitary) are intact.",
"   </p>",
"   <p>",
"    The reduced set point for plasma osmolality has been ascribed to a hemodynamic stimulus for ADH release and thirst caused by vasodilation and resultant arterial underfilling. However, intrathoracic blood volume expansion using head out of water immersion does not correct hypoosmolality in pregnant women.",
"   </p>",
"   <p>",
"    There is evidence that hyponatremia of pregnancy is mediated by hormonal factors. The fall in the plasma sodium concentration during pregnancy correlates closely with increased production of hCG [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Furthermore, the administration of hCG to normal women during the luteal phase of the menstrual cycle can induce a similar resetting of the thresholds for ADH release and thirst [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]. Rather than acting directly, hCG appears to produce these changes via the release of relaxin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/26\">",
"     26",
"    </a>",
"    ]. As an example, hyponatremia in pregnant rats can be corrected by the administration of antirelaxin antibodies or by ovariectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/27\">",
"     27",
"    </a>",
"    ]. As noted above, relaxin also plays an important role in the increased glomerular filtration rate in pregnancy (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Mechanisms'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Attempts to correct the physiologic hyponatremia of pregnancy are both unnecessary (the change is mild and asymptomatic) and ineffective. Resetting of the osmostat means that the plasma sodium concentration will be maintained at the new level despite variations in water or sodium intake.",
"   </p>",
"   <p>",
"    The plasma sodium concentration spontaneously rises to prepregnancy levels within one to two months after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/31,33\">",
"     31,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Increased protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary protein excretion rises in normal pregnancy from the nonpregnant level of about 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to about 180 to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in the third trimester. This may result in a positive dipstick result when a concentrated urine sample is examined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23544?source=see_link\">",
"     \"Evaluation of proteinuria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in proteinuria that occurs during late pregnancy in women with preexisting proteinuria is more exaggerated than would be expected from the increased GFR alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chronic respiratory alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minute ventilation rises in early pregnancy and continues to increase until term, leading to a modest fall in the pCO2 (to 27 to 32 mmHg) and mild respiratory alkalosis. These changes are due to direct stimulation of the central respiratory centers by progesterone&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/35\">",
"     35",
"    </a>",
"    ]. The increase in minute ventilation allows maintenance of a high-normal pO2 despite the 20 to 33 percent increase in oxygen consumption in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=see_link\">",
"     \"Respiratory tract changes during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypouricemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum uric acid declines in early pregnancy because of the rise in GFR, reaching a nadir of 2.0 to 3.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (119 to 178",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    by 22 to 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/36\">",
"     36",
"    </a>",
"    ]. Thereafter, the uric acid level begins to rise, reaching nonpregnant levels by term. The late gestational rise in uric acid is attributed to increased renal tubular absorption of urate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Decrease in serum anion gap",
"    </span>",
"    &nbsp;&mdash;&nbsp;For reasons that are not well understood, there appears to be a small reduction in serum anion gap in pregnant women. This was shown in a cross-sectional study of 119 normal pregnant women (6 in the first trimester, 47 in the second trimester, 59 in the third trimester, and 13 postpartum) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/37\">",
"     37",
"    </a>",
"    ]. The serum anion gap was modestly but significantly lower in pregnancy than postpartum (8.5 versus 10.7).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Impaired tubular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is associated with reductions in fractional reabsorption of glucose, amino acids, and beta microglobulin, which results in higher rates of urinary excretion. Thus, pregnant patients may exhibit glucosuria and aminoaciduria in the absence of hyperglycemia or renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     POLYURIA AND DIABETES INSIPIDUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although urinary frequency due to changes in lower urinary tract function is common in pregnancy, true polyuria, defined as urine output exceeding 3",
"    <span class=\"nowrap\">",
"     L/day,",
"    </span>",
"    typically does not occur. Transient diabetes insipidus of pregnancy is a rare, but important cause of pathologic polyuria, often accompanied by hypernatremia in settings where water intake is restricted. This disorder is related to increased metabolism of antidiuretic hormone (ADH, also called vasopressin).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Transient DI of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidiuretic hormone (ADH) increases renal water reabsorption and decreases urine output. This effect is mediated by activation of the V2 receptor in the renal collecting tubules, resulting in enhanced renal water reabsorption and the formation of concentrated urine. Between the eighth week and mid pregnancy, the metabolic clearance of ADH increases four- to six-fold because of an increase in vasopressinase (also known as oxytocinase), which is produced by the placenta. Enzyme activity continues to increase, peaking in the third trimester, remaining high during labor and delivery, and then falling to undetectable levels two to four weeks postpartum. In most pregnant women, plasma concentrations of ADH remain in the normal range, despite increased metabolic clearance, because of a compensatory increase in ADH production by the pituitary gland. As a result, most women do not become polyuric.",
"   </p>",
"   <p>",
"    A small number of pregnant women, however, develop transient DI, which is underdiagnosed because polyuria is often considered normal during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/33,38-44\">",
"     33,38-44",
"    </a>",
"    ]. The possibility of this disorder should be considered in women with intense polydipsia and polyuria in the third trimester. The diagnosis is supported by the findings of a high-normal plasma sodium (the plasma sodium concentration in normal pregnancy typically is approximately 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    lower than in nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/34\">",
"     34",
"    </a>",
"    ]) in combination with an inappropriately low urine osmolality (ie, below that of plasma) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Hypernatremia can occur if water intake is restricted, as in the peripartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/40,42,45\">",
"     40,42,45",
"    </a>",
"    ]. If unrecognized and untreated, hypernatremia can result in serious neurologic consequences in both the mother and fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that women with transient DI associated with pregnancy have higher than normal pregnancy-related vasopressinase levels or activity. Women with multiple gestations, because of a larger placental volume, have higher circulating levels of vasopressinase and thus are more likely to experience polyuria. DI related in increased vasopressinase activity resolves postpartum and does not usually recur in subsequent pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40375269\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient DI of pregnancy can be effectively treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP, 5 to 20 mcg intranasally or 2 to 5 mcg subcutaneously every 12 to 24 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/40\">",
"     40",
"    </a>",
"    ]. Desmopressin is a vasopressin analog that is resistant to degradation by vasopressinase [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/38,43,46\">",
"     38,43,46",
"    </a>",
"    ]. No adverse maternal or fetal effects from desmopressin use during pregnancy have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/47\">",
"     47",
"    </a>",
"    ]. We suggest restriction of water intake to 1000 mL per day during desmopressin therapy to avoid the development of iatrogenic hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the rare patients who develop hypernatremia, simultaneous water administration (either orally or intravenously) is necessary to correct the total body water deficit. The serum sodium concentration should be closely monitored and the rate of correction limited to no more than 12",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per day to avoid cerebral edema from a rapid fall in serum osmolality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hypernatremia\", section on 'Step two: choose a rate of correction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40375185\">",
"    <span class=\"h2\">",
"     Subclinical central or nephrogenic DI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some pregnant women with signs and symptoms of DI have subclinical central or nephrogenic DI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/38,43,48\">",
"     38,43,48",
"    </a>",
"    ]. On careful questioning, they typically describe polyuria and polydipsia prior to pregnancy, with transient worsening of symptoms during pregnancy. In these cases, polyuria tends to recur with every pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40375199\">",
"    <span class=\"h2\">",
"     DI associated with hepatic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;DI can develop at term in women with a normally functioning hypothalamic-pituitary axis and no previous disturbance of water balance. In such women, increased circulating levels of vasopressinase are often associated with preeclampsia, HELLP syndrome, or acute fatty liver of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/43,44,49,50\">",
"     43,44,49,50",
"    </a>",
"    ]. The mechanism is decreased degradation of vasopressinase due to hepatic dysfunction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    , an analog of ADH that is not sensitive to the vasopressinase, is the preferred treatment and it should be given at dosages equal to or slightly higher than those used to treat neurogenic DI in nonpregnant patients. Arginine vasopressin, the form of ADH secreted by the neurohypophysis, is degraded by the high levels of vasopressin found in this form of the syndrome, and is therefore ineffective",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other causes of DI in pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some women develop transient polyuria that is responsive to vasopressin, as well as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      , that recurs in subsequent pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/38\">",
"       38",
"      </a>",
"      ]. Limited secretory reserve may play an important role in this setting, as the patient cannot compensate for even a modest increase in ADH catabolism.",
"     </li>",
"     <li>",
"      True vasopressin- and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      -resistant nephrogenic DI has been reported in a few women [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/38,51\">",
"       38,51",
"      </a>",
"      ]. The mechanism is uncertain, but spontaneous resolution occurs after delivery.",
"     </li>",
"     <li>",
"      Central DI rarely occurs postpartum in women with severe hemorrhage at delivery and subsequent hypopituitarism [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"       \"Causes of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transient central DI has been associated with acute fatty liver of pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24072/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link\">",
"       \"Acute fatty liver of pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ureteral dilatation (hydronephrosis and hydroureter) is common during pregnancy, and results from hormonal effects, external compression, and intrinsic changes in the ureteral wall. Kidney size also increases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Urinary tract changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinary frequency and nocturia are among the most common pregnancy-related complaints, but usually require no specific treatment. Urinary incontinence also can occur during pregnancy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Urinary symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glomerular filtration rate (GFR) and renal blood flow rise markedly during pregnancy, resulting in a physiologic fall in the serum creatinine concentration. A serum creatinine of 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in a pregnant woman probably reflects significant renal insufficiency. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Renal hemodynamics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most clinical settings, including preeclampsia and pregnant women with mild renal insufficiency, exact knowledge of the GFR is not required. Whether the GFR is changing or is stable is best determined by monitoring changes in the serum creatinine concentration. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Estimation of GFR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other changes in pregnant women include chronic respiratory alkalosis and mild hyponatremia. Fractional absorption of glucose, amino acids, and beta microglobulin are decreased, which can lead to mild glucosuria and aminoaciduria. Protein excretion increases. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Other changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The release of vasopressinases from the placenta results in an approximate four-fold increase rate of ADH catabolism, but ADH levels remain normal because of a concomitant rise in the production of ADH by the pituitary gland. Women who have higher than normal vasopressinase levels or decreased vasopressin reserves may develop gestational diabetes insipidus. This disorder can be effectively treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      (dDAVP). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Polyuria and diabetes insipidus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/1\">",
"      Bailey RR, Rolleston GL. Kidney length and ureteric dilatation in the puerperium. J Obstet Gynaecol Br Commonw 1971; 78:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/2\">",
"      Rasmussen PE, Nielsen FR. Hydronephrosis during pregnancy: a literature survey. Eur J Obstet Gynecol Reprod Biol 1988; 27:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/3\">",
"      Beydoun SN. Morphologic changes in the renal tract in pregnancy. Clin Obstet Gynecol 1985; 28:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/4\">",
"      Irving SO, Burgess NA. Managing severe loin pain in pregnancy. BJOG 2002; 109:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/5\">",
"      Dure-Smith P. Pregnancy dilatation of the urinary tract. The iliac sign and its significance. Radiology 1970; 96:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/6\">",
"      Mattingly RF, Borkowf HI. Clinical implications of ureteral reflux in pregnancy. Clin Obstet Gynecol 1978; 21:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/7\">",
"      Heidrick WP, Mattingly RF, Amberg JR. Vesicoureteral reflux in pregnancy. Obstet Gynecol 1967; 29:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/8\">",
"      Nel JT, Diedericks A, Joubert G, Arndt K. A prospective clinical and urodynamic study of bladder function during and after pregnancy. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/9\">",
"      Francis, WJA. Disturbances of bladder function in relation to pregnancy. J Obstet Gynaecol Br Emp 1960; 43:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/10\">",
"      Stanton SL, Kerr-Wilson R, Harris VG. The incidence of urological symptoms in normal pregnancy. Br J Obstet Gynaecol 1980; 87:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/11\">",
"      van Brummen HJ, Bruinse HW, van der Bom JG, et al. How do the prevalences of urogenital symptoms change during pregnancy? Neurourol Urodyn 2006; 25:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/12\">",
"      Thorp JM Jr, Norton PA, Wall LL, et al. Urinary incontinence in pregnancy and the puerperium: a prospective study. Am J Obstet Gynecol 1999; 181:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/13\">",
"      Aslan D, Aslan G, Yamazhan M, et al. Voiding symptoms in pregnancy: an assessment with international prostate symptom score. Gynecol Obstet Invest 2003; 55:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/14\">",
"      Parboosingh J, Doig A. Renal nyctohemeral excretory patterns of water and solutes in normal human pregnancy. Am J Obstet Gynecol 1973; 116:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/15\">",
"      Cutner A, Cardozo LD, Benness CJ. Assessment of urinary symptoms in early pregnancy. Br J Obstet Gynaecol 1991; 98:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/16\">",
"      Wesnes SL, Rortveit G, B&oslash; K, Hunskaar S. Urinary incontinence during pregnancy. Obstet Gynecol 2007; 109:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/17\">",
"      Wijma J, Potters AE, de Wolf BT, et al. Anatomical and functional changes in the lower urinary tract following spontaneous vaginal delivery. BJOG 2003; 110:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/18\">",
"      Weidner AC, South MM, Sanders DB, Stinnett SS. Change in urethral sphincter neuromuscular function during pregnancy persists after delivery. Am J Obstet Gynecol 2009; 201:529.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/19\">",
"      van Geelen JM, Lemmens WA, Eskes TK, Martin CB Jr. The urethral pressure profile in pregnancy and after delivery in healthy nulliparous women. Am J Obstet Gynecol 1982; 144:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/20\">",
"      Almeida FA, Pavan MV, Rodrigues CI. The haemodynamic, renal excretory and hormonal changes induced by resting in the left lateral position in normal pregnant women during late gestation. BJOG 2009; 116:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/21\">",
"      Davison JM, Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 1980; 18:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/22\">",
"      Gant NF, Chand S, Whalley PJ, MacDonald PC. The nature of pressor responsiveness to angiotensin II in human pregnancy. Obstet Gynecol 1974; 43:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/23\">",
"      Danielson LA, Conrad KP. Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. J Clin Invest 1995; 96:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/24\">",
"      Deng A, Engels K, Baylis C. Impact of nitric oxide deficiency on blood pressure and glomerular hemodynamic adaptations to pregnancy in the rat. Kidney Int 1996; 50:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/25\">",
"      Conrad KP, Jeyabalan A, Danielson LA, et al. Role of relaxin in maternal renal vasodilation of pregnancy. Ann N Y Acad Sci 2005; 1041:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/26\">",
"      Danielson LA, Sherwood OD, Conrad KP. Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest 1999; 103:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/27\">",
"      Novak J, Danielson LA, Kerchner LJ, et al. Relaxin is essential for renal vasodilation during pregnancy in conscious rats. J Clin Invest 2001; 107:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/28\">",
"      C&ocirc;t&eacute; AM, Firoz T, Mattman A, et al. The 24-hour urine collection: gold standard or historical practice? Am J Obstet Gynecol 2008; 199:625.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/29\">",
"      Smith MC, Moran P, Ward MK, Davison JM. Assessment of glomerular filtration rate during pregnancy using the MDRD formula. BJOG 2008; 115:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/30\">",
"      Alper AB, Yi Y, Webber LS, et al. Estimation of glomerular filtration rate in preeclamptic patients. Am J Perinatol 2007; 24:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/31\">",
"      Lindheimer MD, Barron WM, Davison JM. Osmoregulation of thirst and vasopressin release in pregnancy. Am J Physiol 1989; 257:F159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/32\">",
"      Davison JM, Shiells EA, Philips PR, Lindheimer MD. Serial evaluation of vasopressin release and thirst in human pregnancy. Role of human chorionic gonadotrophin in the osmoregulatory changes of gestation. J Clin Invest 1988; 81:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/33\">",
"      Lindheimer MD, Barron WM, Davison JM. Osmotic and volume control of vasopressin release in pregnancy. Am J Kidney Dis 1991; 17:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/34\">",
"      Davison JM, Shiells EA, Philips PR, Lindheimer MD. Influence of humoral and volume factors on altered osmoregulation of normal human pregnancy. Am J Physiol 1990; 258:F900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/35\">",
"      Lim VS, Katz AI, Lindheimer MD. Acid-base regulation in pregnancy. Am J Physiol 1976; 231:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/36\">",
"      Lind T, Godfrey KA, Otun H, Philips PR. Changes in serum uric acid concentrations during normal pregnancy. Br J Obstet Gynaecol 1984; 91:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/37\">",
"      Akbari A, Wilkes P, Lindheimer M, et al. Reference intervals for anion gap and strong ion difference in pregnancy: a pilot study. Hypertens Pregnancy 2007; 26:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/38\">",
"      D&uuml;rr JA. Diabetes insipidus in pregnancy. Am J Kidney Dis 1987; 9:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/39\">",
"      Durr JA, Hoggard JG, Hunt JM, Schrier RW. Diabetes insipidus in pregnancy associated with abnormally high circulating vasopressinase activity. N Engl J Med 1987; 316:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/40\">",
"      Brewster UC, Hayslett JP. Diabetes insipidus in the third trimester of pregnancy. Obstet Gynecol 2005; 105:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/41\">",
"      Aleksandrov N, Audibert F, Bedard MJ, et al. Gestational diabetes insipidus: a review of an underdiagnosed condition. J Obstet Gynaecol Can 2010; 32:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/42\">",
"      Sherer DM, Cutler J, Santoso P, et al. Severe hypernatremia after cesarean delivery secondary to transient diabetes insipidus of pregnancy. Obstet Gynecol 2003; 102:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/43\">",
"      Durr JA, Lindheimer MD. Diagnosis and management of diabetes insipidus during pregnancy. Endocr Pract 1996; 2:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/44\">",
"      Katz VL, Bowes WA Jr. Transient diabetes insipidus and preeclampsia. South Med J 1987; 80:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/45\">",
"      Hanson RS, Powrie RO, Larson L. Diabetes insipidus in pregnancy: a treatable cause of oligohydramnios. Obstet Gynecol 1997; 89:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/46\">",
"      Davison JM, Sheills EA, Philips PR, et al. Metabolic clearance of vasopressin and an analogue resistant to vasopressinase in human pregnancy. Am J Physiol 1993; 264:F348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/47\">",
"      Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998; 53:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/48\">",
"      Iwasaki Y, Oiso Y, Kondo K, et al. Aggravation of subclinical diabetes insipidus during pregnancy. N Engl J Med 1991; 324:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/49\">",
"      Hadi HA, Mashini IS, Devoe LD. Diabetes insipidus during pregnancy complicated by preeclampsia. A case report. J Reprod Med 1985; 30:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/50\">",
"      Ferrara JM, Malatesta R, Kemmann E. Transient nephrogenic diabetes insipidus during toxemia in pregnancy. Diagn Gynecol Obstet 1980; 2:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/51\">",
"      Ford, SM Jr, Lumpkin, HL III. Transient vasopressin-resistant diabetes insipidus of pregnancy. Obstet Gynecol 1986; 68:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24072/abstract/52\">",
"      Kennedy S, Hall PM, Seymour AE, Hague WM. Transient diabetes insipidus and acute fatty liver of pregnancy. Br J Obstet Gynaecol 1994; 101:387.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 404 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-23D1513A50-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24072=[""].join("\n");
var outline_f23_32_24072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      URINARY TRACT CHANGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Increased renal size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ureters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      URINARY SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Frequency and nocturia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Urgency and incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Postpartum changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RENAL HEMODYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Increase in GFR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Estimation of GFR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHER CHANGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mild hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Increased protein excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chronic respiratory alkalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypouricemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Decrease in serum anion gap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Impaired tubular function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      POLYURIA AND DIABETES INSIPIDUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Transient DI of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40375269\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40375185\">",
"      Subclinical central or nephrogenic DI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40375199\">",
"      DI associated with hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other causes of DI in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/404\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/404|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37821\" title=\"figure 1\">",
"      Hemodynamic changes in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/404|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/12/6347\" title=\"table 1\">",
"      Hemodynamics kidney pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=related_link\">",
"      Acute kidney injury (acute renal failure) in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23544?source=related_link\">",
"      Evaluation of proteinuria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13274?source=related_link\">",
"      Maternal endocrine and metabolic adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38340?source=related_link\">",
"      Nephrolithiasis during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=related_link\">",
"      Respiratory tract changes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=related_link\">",
"      Treatment of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=related_link\">",
"      Treatment of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=related_link\">",
"      Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_32_24073="Oxygen carriers as alternatives to red cell transfusion";
var content_f23_32_24073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oxygen carriers as alternatives to red cell transfusion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/32/24073/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24073/contributors\">",
"     Joy L Fridey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/32/24073/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24073/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/32/24073/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/32/24073/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/32/24073/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of &ldquo;artificial blood&rdquo; or a &ldquo;blood substitute&rdquo; has been one of the great expectations of biotechnology and modern medicine. It is generally understood that no manufactured substance can perform the cellular and molecular functions of blood, but these terms remain popular with the media and the public. In the past decades, research efforts have been directed toward developing products that have one main purpose: to perform the oxygen-carrying and gas transport function of red blood cells. These products are referred to as oxygen carriers (OC) or oxygen therapeutics.",
"   </p>",
"   <p>",
"    At the turn of the twenty-first century there was great optimism that rapidly advancing technology would lead to the development of oxygen carriers that could be used in a variety of clinical settings. Many products were in Phase III clinical trials, but this process was impeded by reports of side effects and regulatory concerns about safety. Development of some products was halted. There were allegations that some companies may have misled investors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/1\">",
"     1",
"    </a>",
"    ] or withheld outcome results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/2\">",
"     2",
"    </a>",
"    ]. Inability to obtain regulatory approval and sustain investor support resulted in the withdrawal of many products from clinical trials. In 2009, the remaining two companies ceased manufacture of their oxygen therapeutics and filed for bankruptcy. Currently, there are no clinical trials underway in the US for any products, and none is available on a compassionate-use basis.",
"   </p>",
"   <p>",
"    In spite of these disappointing setbacks, there continues to be a pressing need for oxygen therapeutics, and it is unlikely that work in this field will cease altogether. Insights regarding the basic biology and physiology of hemoglobin and gas transport systems will lead to development of new products. It is also possible that modification of previously-tested carriers will result in new clinical trials. Because of ongoing medical and public interest in oxygen therapeutics, this topic review will provide general information about oxygen carriers, and will review clinical and historical highlights [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of human red cells for transfusion and the normal oxygen delivery system are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=see_link\">",
"     \"Oxygen delivery and consumption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL PERSPECTIVE AND RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts to develop substances that could replace blood date to the 17th century and continued into the mid-1800s when hemoglobin solutions were infused experimentally into humans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These efforts resulted in significant morbidity and mortality, mostly from the nephrotoxic effects of free hemoglobin and red cell stroma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/8\">",
"     8",
"    </a>",
"    ]. These results discouraged further activity of consequence, but research was renewed when the wars of the 20th century again raised awareness that an easily stored, transportable, and abundant oxygen carrier was needed.",
"   </p>",
"   <p>",
"    The HIV epidemic was a watershed phenomenon that catalyzed early research in the 1980s and propelled the search for such a product to peak levels in the 1990s and 2000s. The potential contamination of blood by other viruses, bacteria, and parasites, the need for pre-transfusion compatibility testing such as crossmatching, and special storage requirements, as well as immunologic complications of allogeneic blood transfusion, also contributed to this renewed interest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=see_link\">",
"     \"Transfusion transmitted HIV infection and AIDS\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H6#H6\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While efforts to develop oxygen carriers were underway, the infectious risks of transfusion continued to fall dramatically because of improvements in blood donor screening and testing. This, as well as simultaneous efforts to develop pathogen inactivation technologies, decreased the sense of urgency for oxygen carriers. However, in a survey sponsored by VI Technologies, a biotechnology company specializing in blood pathogen inactivation, at least 84 percent of the 502 Americans surveyed essentially still perceived blood as a Trojan horse [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/9\">",
"     9",
"    </a>",
"    ]. This thinking may continue to perpetuate safety arguments as the basis for pursuing laboratory-derived products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link\">",
"     \"Blood donor medical history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Public opinion notwithstanding, a public health problem that could continue to drive development of these products is looming within the United States and the world: blood shortages. It is projected that by the year 2030 there could be a shortfall of 4 million units annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Worldwide, the current need is for over 200 million units per year in countries that lack the testing and storage capabilities for supporting an allogeneic blood supply [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THE IDEAL OXYGEN CARRIER",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ideal substance for carrying (and delivering) oxygen would have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immediate availability",
"     </li>",
"     <li>",
"      Effective oxygen carrying capacity and provision of volume expansion",
"     </li>",
"     <li>",
"      Appropriate physiological interaction with nitric oxide (NO)",
"     </li>",
"     <li>",
"      Non-infectious",
"     </li>",
"     <li>",
"      Minimal side effects",
"     </li>",
"     <li>",
"      Viability over a range of storage temperatures",
"     </li>",
"     <li>",
"      A long shelf life",
"     </li>",
"     <li>",
"      Universal compatibility and elimination of crossmatching",
"     </li>",
"     <li>",
"      Cost effectiveness",
"     </li>",
"     <li>",
"      An adequate supply",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional benefit would be the ability of chemically or genetically modified products to work in special and specific clinical situations (ie, a \"boutique\" approach to oxygenation therapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major categories of oxygen carriers were developed (",
"    <a class=\"graphic graphic_table graphicRef73791 \" href=\"UTD.htm?10/40/10893\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin-based oxygen carriers (HBOCs)",
"     </li>",
"     <li>",
"      Perfluorocarbons (PFCs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hemoglobin-based oxygen carriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin for HBOCs is derived from two mammalian sources: animal (bovine) and human blood, the latter primarily from outdated red cell units. After separation from red cell stroma through ultrafiltration and purification [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/13\">",
"     13",
"    </a>",
"    ], mammalian-derived hemoglobin must undergo chemical modification (eg, cross-linking, pyridoxylation, polymerization, pegylation), which prevents the dissociation of hemoglobin from its native tetrameric configuration into its basic &alpha;&beta; dimers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/14\">",
"     14",
"    </a>",
"    ]. Polymerization converts the four-chain hemoglobin moiety into larger two to four hemoglobin molecule-containing polymers. Cross-linking of alpha chains prevents dissociation of the hemoglobin molecule into alpha-beta dimers, which, with a molecular weight of 34,000, would otherwise be small enough to be filtered by the glomerulus and cause hemoglobinuria.",
"   </p>",
"   <p>",
"    Polymerization and cross linking appeared to have largely solved some of the problems associated with unmodified stroma-free hemoglobin. Specifically, product half life increased from a few hours to 12 to 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/15\">",
"     15",
"    </a>",
"    ], glomerular filtration of the products was decreased, reducing or effectively eliminating nephrotoxicity, and oxygenation was improved as a result of the lowered oxygen affinity of some of these products (eg, P50 as high as 54 mm Hg) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/14,16,17\">",
"     14,16,17",
"    </a>",
"    ]. However, trials of one of the cross-linked products in US and European trauma patients demonstrated increased mortality, and, consequently, development of at least one particular HBOC formulation was halted for this particular reason [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another type of modification, formation of liposome-encapsulated hemoglobin (LEH), seemed to confer advantages such as a much longer intravascular half-life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/15\">",
"     15",
"    </a>",
"    ], and the potential for freeze-dried storage. Significant immunologic reactions, mostly due to interactions with the liposomal membrane, stalled the development of this oxygen carrier [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemoglobin can also be produced through recombinant technology. This approach showed promise in the early 1990s and involved the use of E. coli transfected with human hemoglobin genes. However, in animal models, vasoconstriction attributed to scavenging of nitric oxide by the recombinant product and elevated amylase and lipase levels suggesting decreased pancreatic perfusion, were observed. [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Efforts on this product were abandoned in 2003.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Perfluorocarbons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perfluorocarbon (PFC) products are not newcomers to the field. The now decades-old magazine cover depicting a living, breathing mouse submerged in a beaker of liquid PFC is a well-remembered image from 1966 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1989 the US Food and Drug Administration (FDA) approved Fluosol, a PFC, for perfusion of ischemic tissues in the setting of percutaneous transluminal coronary angioplasty. This was the first such product ever licensed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/28\">",
"     28",
"    </a>",
"    ]. Lacking commercial success, Fluosol was withdrawn from the market in 1994. However, work on PFCs did not come to a halt. Results of a European Phase III trial of perflubron emulsion in non-cardiac patients suggested that, when used in conjunction with acute normovolemic hemodilution, this product resulted in slightly lower requirements for allogeneic blood compared with the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PFCs are inert compounds in which fluorine replaces hydrogen atoms. Water insolubility necessitates emulsification; egg yolk phospholipid is the emulsifying agent for the product used in Phase III trials [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/30\">",
"     30",
"    </a>",
"    ]. The plasma half-life of PFCs is about 12 hours. They are stable for up to two years, and must be refrigerated at about 4&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike HBOCs, PFCs do not carry gases. Rather, because of their decreased surface tension and intramolecular action, they act as excellent solvents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/13,30\">",
"     13,30",
"    </a>",
"    ], and have essentially unlimited ability to absorb gases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/15\">",
"     15",
"    </a>",
"    ]. The oxygen-carrying capacity is linearly related to the pO2; patients receiving these agents require high concentrations of supplemental oxygen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FOCUS OF CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical areas for which oxygen carriers were considered to have the greatest potential applicability were cardiovascular elective surgery and hemorrhagic shock related to trauma and acute blood loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the surgical setting, the goal was to postpone, reduce, or eliminate the need for allogeneic blood, especially in cardiovascular procedures (including priming of the bypass pump) and situations in which bleeding could exceed anticipated levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/13,31\">",
"     13,31",
"    </a>",
"    ]. In some studies, patients who received hemoglobin-based oxygen carriers (HBOC) for cardiac, aortic, or emergency surgery required substantially fewer allogeneic red cell units, compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15033255\">",
"    <span class=\"h2\">",
"     Hemorrhagic shock of trauma and acute blood loss",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Animal experiments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because animal data suggested that the outcome of hemorrhagic shock correlated with tissue hypoxia, it was hypothesized that in humans, acellular, oxygen-carrying resuscitation fluids could improve outcomes when blood was not immediately available [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Hemoglobin solutions and perfluorochemical compounds were used to resuscitate animals with severe hemorrhagic shock, and appeared to result in more rapid restoration of normal tissue metabolism and improved survival compared with crystalloid solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one protocol, 16 dogs were phlebotomized until hypotension, acidemia, and diminished mixed venous PO2 occurred. The animals were then randomly assigned to undergo resuscitation with lactated Ringer's solution or an oxygen-carrying perfluorochemical emulsion [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/38\">",
"       38",
"      </a>",
"      ]. Perfluorochemical treatment resulted in more rapid normalization of mixed venous PO2, and improved survival at three hours (100 versus 63 percent).",
"     </li>",
"     <li>",
"      In induced hemorrhagic shock in pigs, use of a blood substitute manufactured from polymerized bovine hemoglobin resulted in improved hemodynamics and transcutaneous tissue oxygen tension and decreased need for transfusion compared with use of a 6 percent hydroxyethyl starch (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/13/9430?source=see_link\">",
"       hetastarch",
"      </a>",
"      ) preparation (Hextend) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Human studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apparently beneficial effects of blood substitutes observed in animals were not replicated in at least two human trials.",
"   </p>",
"   <p>",
"    One study randomly assigned 112 patients with traumatic hemorrhagic shock and unstable vital signs to receive either diaspirin cross-linked hemoglobin solution or saline. Patients who received the oxygen-carrying blood substitute had significantly higher mortality at 2 and 28 days (46 versus 17 percent at 28 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/19\">",
"     19",
"    </a>",
"    ]. The mechanism by which diaspirin cross-linked hemoglobin might have worsened outcomes is unclear, but may have been related to its actions as a nitric oxide scavenger",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its pressor effects, which may have accelerated the rate of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Vasoactivity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A multicenter randomized phase III trial compared the initial use of a human polymerized hemoglobin preparation (PolyHeme) to crystalloid in 714 injured patients with a systolic pressure &le;90 mm Hg. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary outcome measure, 30-day mortality, was higher in the PolyHeme arm than in the crystalloid arm (13.4 versus 9.6 percent, respectively), although this difference was not statistically significant.",
"     </li>",
"     <li>",
"      Subgroup analysis indicated a significantly higher 30-day mortality in those suffering blunt trauma who received PolyHeme (18 versus 10 percent, respectively).",
"     </li>",
"     <li>",
"      Adverse events were more common in the group receiving PolyHeme, and included a significantly higher incidence of coagulopathy and myocardial infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Ethical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;In trauma situations, oxygen carriers have the potential to provide hemodynamic stabilization until allogeneic blood products can be made available. However, concerns existed about whether participants in trauma studies in which oxygen carriers might be used would have ample opportunity to provide informed consent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. As an example of how this was addressed in one phase III trial (PolyHeme versus crystalloid), patient enrollment occurred under an FDA regulation (21CFRSection50.24), which provided an exemption from informed consent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/42\">",
"     42",
"    </a>",
"    ]. Ethical considerations such as this will continue to inform the design of trials in trauma and other patients who may not be able to provide informed consent prior to infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patients unable to receive red cell transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;That medical patients who may not accept or be able to tolerate allogeneic blood could potentially survive hemorrhagic or hemolytic catastrophes if infused with an oxygen carrier, was demonstrated by these studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one reported case, an exsanguinating patient with hemolytic anemia was in all probability saved by the infusion of an HBOC [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/15,46\">",
"       15,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who, for religious or other reasons (eg, Jehovah's Witnesses), may not accept allogeneic transfusions [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/47-54\">",
"       47-54",
"      </a>",
"      ], may agree to receive an oxygen carrier. Reported cases in which patients were successfully treated with a PFC or HBOC included patients with trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/49,55\">",
"       49,55",
"      </a>",
"      ], severe post-operative anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/52\">",
"       52",
"      </a>",
"      ], acute chest syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/51\">",
"       51",
"      </a>",
"      ], abruptio placenta [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/53\">",
"       53",
"      </a>",
"      ], and chemotherapy-induced anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/54,56\">",
"       54,56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=see_link\">",
"       \"The approach to the patient who refuses blood transfusion\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other potential uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small size of HBOC and PFC compared with red cells (&lt;0.1 versus 7 microns, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/13\">",
"     13",
"    </a>",
"    ] theoretically could enable penetration of poorly oxygenated areas not accessible to red cells. The potential to reach these tissues led to optimism that such products could be used in vaso-occlusive crises, such as stroke and pain crises associated with sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The availability of such products could be especially important in sickle cell disease if a patient is unable to receive allogeneic blood due to the presence of multiple antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/59\">",
"     59",
"    </a>",
"    ]. It was also proposed that the radio- and chemo-sensitivity of some tumors could be enhanced by the use of oxygen carriers, one of which was previously under development for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FDA will ultimately determine the clinical uses for any products that are developed in the future. Since 1991, the FDA has been communicating safety and efficacy expectations to the biotechnology community [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In late 1999, the agency conducted a workshop with the National Institutes of Health that extensively addressed possible clinical uses for such oxygen carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/63\">",
"     63",
"    </a>",
"    ]. These documents provide important insights into the philosophy and expectations of the FDA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBOC and PFC, as previously formulated, would likely not have been indicated in patients with long-term or chronic transfusion needs. Because these products had short intravascular activity, patients with the anemia of chronic disease, leukemia, or chemotherapy-induced anemia, as an example, would not receive the prolonged oxygen-carrying benefit that red cells, with an average life span of 120 days, offer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=see_link\">",
"     \"Red blood cell survival: Normal values and measurement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A major limitation of PFC was the requirement for high doses of supplemental oxygen. Thus, without supplemental oxygen availability, PFC use would probably be restricted to hospital, rather than field, environments [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     HBOC-associated side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major problems associated with HBOC included:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Vasoactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBOC products were associated with vasoconstriction and pressor effects [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. One proposed etiology was that nitric oxide (NO; also called endothelial derived relaxing factor, EDRF), which contributes to vasodilation, was scavenged by hemoglobin in the oxygen carrier [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/13,66-72\">",
"     13,66-72",
"    </a>",
"    ] and caused systemic vasoconstriction, decreased blood flow, release of proinflammatory mediators, and loss of platelet inactivation, potentially leading to thrombosis in the heart",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/14,41,73\">",
"     14,41,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link&amp;anchor=H11#H11\">",
"     \"Structure and function of normal human hemoglobins\", section on 'Nitric oxide transport'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=see_link&amp;anchor=H3#H3\">",
"     \"Inhaled nitric oxide in adults with pulmonary hypertension\", section on 'Physiology'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H22\">",
"     'Myocardial infarction and death'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other proposed mechanisms invoked the autoregulatory vasoconstrictive reflex of excess tissue oxygen concentrations, the oxidation properties of hemoglobin as it degrades, an adrenergic effect caused by the direct action of hemoglobin on peripheral nerves, and carrier interaction with endothelin, a regulator of vascular tone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hemostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in rabbits showed an increased hemostatic effect of HBOC [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/75\">",
"     75",
"    </a>",
"    ], perhaps related to reversal of the inhibitory effect of NO on platelet adhesion and aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Gastrointestinal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal side effects such as nausea, vomiting, diarrhea, dysphagia, bloating, and other symptoms were occasionally reported. Symptoms were usually mild to moderate and often did not require treatment. Lack of availability of nitric oxide in GI tissues was a proposed etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression leading to increased risk of infection was reported in animals, and in possible future trials may warrant increased scrutiny of these agents for this effect in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Interference with laboratory assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effect of HBOCs on laboratory tests was attributed to the high concentration of hemoglobin in plasma that can occur with infusion of HBOC. Tests for liver enzymes, bilirubin, amylase, and others, including optical assays for coagulation times, yielded inaccurate results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The laboratory tests of greatest immediate relevance in critical care settings were not affected by the presence of HBOCs (eg, electrolytes, glucose, blood gases, creatinine [enzymatic methods], PT and aPTT [mechanical methods]) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Myocardial infarction and death",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a seminal publication, a meta-analysis assessed the safety of HBOCs in a total of 3711 patients enrolled in 16 trials involving five different hemoglobin-based products [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/14\">",
"     14",
"    </a>",
"    ]. Compelling conclusions that contributed to the decline of product development were reached:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a significant increase in the risk of death following the use of these agents (RR 1.30; 95% CI 1.05-1.61) when compared with control groups receiving standard treatment (eg, allogeneic blood, lactated Ringer solution, saline,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/13/9430?source=see_link\">",
"       hetastarch",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/27/14772?source=see_link\">",
"       pentastarch",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      There was a significantly increased risk of myocardial infarction among patients receiving HBOCs (RR 2.71; 95% CI 1.67-4.40).",
"     </li>",
"     <li>",
"      Subgroup analysis indicated that these increased risks were not restricted to a particular HBOC preparation or clinical indication (eg, surgery, stroke, trauma).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An accompanying editorial concluded that, given the above findings and the consistency of these results with preclinical evidence of potential toxicity, further phase III trials of HBOCs should not be conducted until it could be shown that these agents were at least as effective in reducing mortality or serious morbidity as the current standards of care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     PFC-associated side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical problems associated with PFC were flu-like symptoms attributed to cytokine-mediated effects, and platelet sequestration in the spleen and liver, causing hepatosplenomegaly, and lowering of the peripheral blood platelet count by as much as 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/13\">",
"     13",
"    </a>",
"    ]. A comprehensive review of PFCs, clinical trials, and adverse effects is available [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sense of decreased urgency for oxygen carriers (see above), adverse effects, and short intravascular life were three obvious hurdles to regulatory approval for continued research and clinical applicability for these agents. There were, however, other issues of concern:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an HBOC had received regulatory approval and licensure, it is estimated that 70,000 kg of hemoglobin would have been required to replace 20 percent of the US red cell transfusions per year [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/82\">",
"     82",
"    </a>",
"    ]. Limitations on availability, management, and manufacturing of raw materials would present challenges for providing this amount of material. Two units of red cells are required to produce one therapeutic HBOC dose as previously formulated. However, the expiration rate of human blood is extremely low, making this a less available source in times of great need. Furthermore, it is not known whether volunteer blood donors would support the raw materials needs of a commercial biotechnology enterprise.",
"   </p>",
"   <p>",
"    Animal-derived hemoglobin would require intensive management of huge herds, and even careful management and sophisticated product purification methodologies may not adequately assuage fears about contagion from source animals. This concern has been reinforced by reports that transfusion was the likely cause of human-to-human transmission of variant Creutzfeldt-Jakob disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. It remains to be seen whether the complex genetic engineering procedures required for producing a recombinant product can be expanded and adequately controlled to meet this need. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link&amp;anchor=H16#H16\">",
"     \"Blood donor medical history\", section on 'Variant Creutzfeldt-Jakob disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link&amp;anchor=H3#H3\">",
"     \"Variant Creutzfeldt-Jakob disease\", section on 'Relationship with BSE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manufacturers of HBOC and PFC were prohibited by federal regulations to discuss possible pricing information for products that were under development or in clinical trials. Given the other challenges facing oxygen carriers, the market potential may have been limited, unless the price of a red cell unit-equivalent approached that of an allogeneic red cell unit, approximately $300 to $400 USD, including crossmatching and other costs. Two earlier HBOC price estimates ranged from $400 to $800 USD per unit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drawing a lesson from the",
"    <span class=\"nowrap\">",
"     solvent/detergent-treated",
"    </span>",
"    plasma story, in which price may originally have played a role in reduced utilization, it is possible that a high price for an oxygen carrier could adversely affect marketability. However, if such products eventually reach the market, cost-benefit analyses will be important, and situations such as trauma, in which a clear life-saving benefit is apparent, may make price irrelevant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Regulation and licensure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen carriers, like other pharmaceuticals and biologics, will have to meet stringent major efficacy and safety requirements in order to gain FDA approval. The optimism in the early 2000s about near-term approval of OCs was squelched by several events, and with these experiences as the backdrop for future regulatory review the bar may be even higher than for previous trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The discontinuation of research into the use of cross-linked hemoglobin because a Phase III trial of a diaspirin cross-linked hemoglobin OC (HemAssist) showed a higher mortality rate in recipients versus controls [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/19,87\">",
"       19,87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cessation of efforts to move recombinant products forward because of reported adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the wake of the HemAssist trial outcome, the FDA expanded the clinical testing requirements for all similar products, causing a deceleration in trial approval and enrollment [",
"      <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/88,89\">",
"       88,89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Compassionate use",
"    </span>",
"    &nbsp;&mdash;&nbsp;As demonstrated by a case report published in 2010, it was difficult, but not completely impossible, to obtain unlicensed products for emergency situations. The publication reported on a Jehovah&rsquo;s Witness patient with acute lymphoblastic leukemia who was successfully treated with 15 units of an unlicensed HBOC for life-threatening anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/90\">",
"     90",
"    </a>",
"    ]. To access this product, it was necessary to obtain an emergency investigational new drug application from the FDA. This patient may have been the last beneficiary of the compassionate use program for oxygen carriers, as one month after this case was submitted for publication, the HBOC manufacturer filed for bankruptcy. No HBOC or PFCs are available on a compassionate use basis in the US at this time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=see_link\">",
"     \"The approach to the patient who refuses blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As for the two products currently in clinical trials, Hemospan (Sangart, San Diego, CA) and HemoTech (HemoBiotech, Dallas, TX), we have been unable to determine from the manufacturers whether these products are available for compassionate use purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND FUTURE PROSPECTS FOR OXYGEN CARRIERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous factors fueled the explosion of research activity into the development of oxygen carriers. Concerns about blood safety and availability, complexities of compatibility testing, a need for products to treat hemorrhagic shock in the field, and a compelling commercial interest in a market potentially worth billions of dollars contributed to this highly competitive and frenetic pursuit. It is a universal disappointment that the promise of safe oxygen carriers did not materialize and that participants may have been significantly affected. With the acuity of retrospection, there has even been speculation that clinical trials may have been premature [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/91\">",
"     91",
"    </a>",
"    ]. However, new and surprising insights into the role and attributes of hemoglobin, particularly its interaction with nitric oxide and its physiologic properties and performance in variously modified states, were obtained.",
"   </p>",
"   <p>",
"    In 2006, the National Heart, Lung, and Blood Institute (NHLBI) convened a workshop to evaluate the scientific issues that were critical to developing hemoglobin-based oxygen carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/92\">",
"     92",
"    </a>",
"    ]. Concerns mainly about adverse cardiovascular events resulted in the development of recommendations for basic research that would be critical to developing safer products, and that could and should lay the foundation for future work.",
"   </p>",
"   <p>",
"    During the current period of retrospection and introspection, work on oxygen carriers does go on. New ideas for HBOC, including coupling of hemoglobin tetramers and other approaches to modifying the size and properties of hemoglobin molecules are examples [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/93\">",
"     93",
"    </a>",
"    ]. Clinical trials to evaluate an oxygenated polyethylene glycol-modified hemoglobin, MP4OX (Hemospan&reg;), for preventing hypotension in patients undergoing elective hip arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/94\">",
"     94",
"    </a>",
"    ] and for safety in prostatectomy cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/32/24073/abstract/95\">",
"     95",
"    </a>",
"    ] have been conducted, the latter of which, a Phase II trial, is currently undergoing FDA review. PFCs have not disappeared from view, and an Asian pharmaceutical company, in collaboration with Alliance Pharmaceutical, was considering new clinical trials for Alliance&rsquo;s PFC product.",
"   </p>",
"   <p>",
"    As clinical trials slowly resume in the US, the lessons of the past decades and a more complete understanding of the physiology of oxygen transport will hopefully lead to safer products that may eventually be licensed by the FDA for specific clinical indications.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     SEC charges Massachusetts biotechnology company and executives with securities fraud. US Securities and Exchange Commission. Litigation Release No. 19376, 9/14/05.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/2\">",
"      Burton TM. Amid alarm bells, a blood substitute keeps pumping. Wall Street Journal 2006; 247:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/3\">",
"      Winslow RM. Blood substitutes: refocusing an elusive goal. Br J Haematol 2000; 111:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/4\">",
"      Stowell CP, Levin J, Spiess BD, Winslow RM. Progress in the development of RBC substitutes. Transfusion 2001; 41:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/5\">",
"      Reid TJ. Hb-based oxygen carriers: are we there yet? Transfusion 2003; 43:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/6\">",
"      Fakhry SM, Sheldon GF. Blood administration, risks, and substitutes. Adv Surg 1995; 28:71.",
"     </a>",
"    </li>",
"    <li>",
"     Baxter Healthcare Corp. Company information.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/8\">",
"      AMBERSON WR, JENNINGS JJ, RHODE CM. Clinical experience with hemoglobin-saline solutions. J Appl Physiol 1949; 1:469.",
"     </a>",
"    </li>",
"    <li>",
"     AABB Weekly Report. July 28, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/10\">",
"      Marwick C. More than a trickle of interest in blood substitutes. JAMA 1994; 271:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/11\">",
"      Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion 1994; 34:464.",
"     </a>",
"    </li>",
"    <li>",
"     Winslow RM. Red cell substitutes: Impact of blood substitutes worldwide. Annual Meeting Compendium. American Association of Blood Banks, Bethesda 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/13\">",
"      Scott MG, Kucik DF, Goodnough LT, Monk TG. Blood substitutes: evolution and future applications. Clin Chem 1997; 43:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/14\">",
"      Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008; 299:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/15\">",
"      Klein HG. The prospects for red-cell substitutes. N Engl J Med 2000; 342:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/16\">",
"      Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids, drugs, or miracle solutions? Anesth Analg 1996; 82:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/17\">",
"      Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol 2003; 285:H1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/18\">",
"      Lamy ML, Daily EK, Brichant JF, et al. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group. Anesthesiology 2000; 92:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/19\">",
"      Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999; 282:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/20\">",
"      Kerner T, Ahlers O, Veit S, et al. DCL-Hb for trauma patients with severe hemorrhagic shock: the European \"On-Scene\" multicenter study. Intensive Care Med 2003; 29:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/21\">",
"      Rollwagen FM, Gafney WC, Pacheco ND, et al. Multiple responses to administration of liposome-encapsulated hemoglobin (LEH): Effects on hematopoiesis and serum IL-6 levels. Exp Hematol 1996; 24:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/22\">",
"      Szebeni J, Wassef NM, Hartman KR, et al. Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion 1997; 37:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/23\">",
"      Rudolph AS, Cliff R, Kwasiborski V, et al. Liposome-encapsulated hemoglobin modulates lipopolysaccharide-induced tumor necrosis factor-alpha production in mice. Crit Care Med 1997; 25:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/24\">",
"      Siegel JH, Fabian M, Smith JA, Costantino D. Use of recombinant hemoglobin solution in reversing lethal hemorrhagic hypovolemic oxygen debt shock. J Trauma 1997; 42:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/25\">",
"      Thompson A, McGarry AE, Valeri CR, Lieberthal W. Stroma-free hemoglobin increases blood pressure and GFR in the hypotensive rat: role of nitric oxide. J Appl Physiol 1994; 77:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/26\">",
"      Olson JS, Foley EW, Rogge C, et al. No scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med 2004; 36:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/27\">",
"      Clark LC Jr, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 1966; 152:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/28\">",
"      Kerins DM. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty. Am J Med Sci 1994; 307:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/29\">",
"      Spahn DR, Waschke KF, Standl T, et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology 2002; 97:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/30\">",
"      Keipert PE, Faithfull NS, Bradley JD, et al. Enhanced oxygen delivery by perflubron emulsion during acute hemodilution. Artif Cells Blood Substit Immobil Biotechnol 1994; 22:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/31\">",
"      Ketcham EM, Cairns CB. Hemoglobin-based oxygen carriers: development and clinical potential. Ann Emerg Med 1999; 33:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/32\">",
"      LaMuraglia GM, O'Hara PJ, Baker WH, et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. J Vasc Surg 2000; 31:299.",
"     </a>",
"    </li>",
"    <li>",
"     Hemosol, Inc. Company announcement. July 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/34\">",
"      Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 1998; 187:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/35\">",
"      Young JS, Fernandez M, Meredith JW. The effect of oxygen delivery-directed resuscitation on splanchnic and hepatic oxygen transport after hemorrhagic shock. J Surg Res 1997; 71:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/36\">",
"      Knudson MM, Bermudez KM, Doyle CA, et al. Use of tissue oxygen tension measurements during resuscitation from hemorrhagic shock. J Trauma 1997; 42:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/37\">",
"      DeAngeles DA, Scott AM, McGrath AM, et al. Resuscitation from hemorrhagic shock with diaspirin cross-linked hemoglobin, blood, or hetastarch. J Trauma 1997; 42:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/38\">",
"      Herschman Z, Cardoso R, Mazur W. Perfluorochemical emulsion for resuscitation of experimental hemorrhagic shock. Crit Care Med 1995; 23:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/39\">",
"      Kochetygov NI, Gorkoun AV, Gerbut KA, et al. Study of therapeutic efficiency of new blood substitutes in experimental hemorrhagic shock. Artif Cells Blood Substit Immobil Biotechnol 1996; 24:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/40\">",
"      Rice J, Philbin N, McGwin G, et al. Bovine polymerized hemoglobin versus Hextend resuscitation in a swine model of severe controlled hemorrhagic shock with delay to definitive care. Shock 2006; 26:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/41\">",
"      Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/42\">",
"      Moore EE, Moore FA, Fabian TC, et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. J Am Coll Surg 2009; 208:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/43\">",
"      Dalton R. Trauma trials leave ethicists uneasy. Nature 2006; 440:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/44\">",
"      Holloway KF. Accidental communities: race, emergency medicine, and the problem of polyheme. Am J Bioeth 2006; 6:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/45\">",
"      Karlawish JH, Hall JB. The controversy over emergency research. A review of the issues and suggestions for a resolution. Am J Respir Crit Care Med 1996; 153:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/46\">",
"      Mullon J, Giacoppe G, Clagett C, et al. Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N Engl J Med 2000; 342:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/47\">",
"      Gannon CJ, Napolitano LM. Severe anemia after gastrointestinal hemorrhage in a Jehovah's Witness: new treatment strategies. Crit Care Med 2002; 30:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/48\">",
"      Marelli TR. Use of a hemoglobin substitute in the anemic Jehovah's Witness patient. Crit Care Nurse 1994; 14:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/49\">",
"      Cothren C, Moore EE, Offner PJ, et al. Blood substitute and erythropoietin therapy in a severely injured Jehovah's witness. N Engl J Med 2002; 346:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/50\">",
"      Anton N, Hitzler JK, Kavanagh BP. Treatment of life-threatening post-haemorrhagic anaemia with cell-free haemoglobin solution in an adolescent Jehovah's Witness. Br J Haematol 2002; 118:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/51\">",
"      Lanzkron S, Moliterno AR, Norris EJ, et al. Polymerized human Hb use in acute chest syndrome: a case report. Transfusion 2002; 42:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/52\">",
"      Lanzinger MJ, Niklason LE, Shannon M, Hill SE. Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth 2005; 52:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/53\">",
"      Cothren CC, Moore EE, Long JS, et al. Large volume polymerized haemoglobin solution in a Jehovah's Witness following abruptio placentae. Transfus Med 2004; 14:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/54\">",
"      Agrawal YP, Freedman M, Szczepiorkowski ZM. Long-term transfusion of polymerized bovine hemoglobin in a Jehovah's Witness following chemotherapy for myeloid leukemia: a case report. Transfusion 2005; 45:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/55\">",
"      Marinaro J, Smith J, Tawil I, et al. HBOC-201 use in traumatic brain injury: case report and review of literature. Transfusion 2009; 49:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/56\">",
"      Donahue LL, Shapira I, Shander A, et al. Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature. Transfusion 2010; 50:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/57\">",
"      Gonzalez P, Hackney AC, Jones S, et al. A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study. J Investig Med 1997; 45:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/58\">",
"      Kaul DK, Liu X, Nagel RL. Ameliorating effects of fluorocarbon emulsion on sickle red blood cell-induced obstruction in an ex vivo vasculature. Blood 2001; 98:3128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/59\">",
"      Raff JP, Dobson CE, Tsai HM. Transfusion of polymerised human haemoglobin in a patient with severe sickle-cell anaemia. Lancet 2002; 360:464.",
"     </a>",
"    </li>",
"    <li>",
"     Stover R. A New Generation of Oxygen Therapeutics. Stover and Associates; LLC; Stamford, CT 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/61\">",
"      Points to consider in the safety evaluation of hemoglobin-based oxygen carriers. Center for Biologics Evaluation and Research. Transfusion 1991; 31:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/62\">",
"      Points to consider on efficacy evaluation of hemoglobin- and perfluorocarbon-based oxygen carriers. Center for Biologics Evaluation and Research. Transfusion 1994; 34:712.",
"     </a>",
"    </li>",
"    <li>",
"     Oxygen Therapeutics as Blood Substitutes. FDA Workshop, September 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/64\">",
"      Cabrales P, Tsai AG, Intaglietta M. Balance between vasoconstriction and enhanced oxygen delivery. Transfusion 2008; 48:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/65\">",
"      Cabrales P. Low oxygen-affinity hemoglobin solution increases oxygenation of partially ischemic tissue during acute anemia. J Am Coll Surg 2010; 210:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/66\">",
"      Buehler PW, Alayash AI. Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems. Transfusion 2004; 44:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/67\">",
"      Sanders KE, Ackers G, Sligar S. Engineering and design of blood substitutes. Curr Opin Struct Biol 1996; 6:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/68\">",
"      Patel RP. Biochemical aspects of the reaction of hemoglobin and NO: implications for Hb-based blood substitutes. Free Radic Biol Med 2000; 28:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/69\">",
"      Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 2003; 348:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/70\">",
"      Tsai AG, Cabrales P, Manjula BN, et al. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood 2006; 108:3603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/71\">",
"      Ritchie AJ, Hartshorn S, Crosbie AE, et al. The action of diaspirin cross-linked haemoglobin blood substitute on human arterial bypass conduits. Eur J Cardiothorac Surg 2000; 18:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/72\">",
"      Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/73\">",
"      De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/74\">",
"      Gulati A, Sharma AC, Singh G. Role of endothelin in the cardiovascular effects of diaspirin crosslinked and stroma reduced hemoglobin. Crit Care Med 1996; 24:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/75\">",
"      Lee DH, Bardossy L, Peterson N, Blajchman MA. o-raffinose cross-linked hemoglobin improves the hemostatic defect associated with anemia and thrombocytopenia in rabbits. Blood 2000; 96:3630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/76\">",
"      Simon DI, Stamler JS, Loh E, et al. Effect of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol 1995; 26:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/77\">",
"      Griffiths E, Cortes A, Gilbert N, et al. Haemoglobin-based blood substitutes and sepsis. Lancet 1995; 345:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/78\">",
"      Langermans JA, Bleeker WK. Haemoglobin-based blood substitutes and infection. Lancet 1995; 345:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/79\">",
"      Ma Z, Monk TG, Goodnough LT, et al. Effect of hemoglobin- and Perflubron-based oxygen carriers on common clinical laboratory tests. Clin Chem 1997; 43:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/80\">",
"      Fergusson DA, McIntyre L. The future of clinical trials evaluating blood substitutes. JAMA 2008; 299:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/81\">",
"      Castro CI, Briceno JC. Perfluorocarbon-based oxygen carriers: review of products and trials. Artif Organs 2010; 34:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/82\">",
"      Kumar R. Recombinant hemoglobins as blood substitutes: a biotechnology perspective. Proc Soc Exp Biol Med 1995; 208:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/83\">",
"      Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/84\">",
"      Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527.",
"     </a>",
"    </li>",
"    <li>",
"     Winslow RM. New Frontiers in Transfusion Medicine 1995. American Association of Blood Banks Teleconference.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/86\">",
"      Biopure Hemopure new user fee likely in November; FDA requests data. Pharmaceutical Approvals Monthly. F-D-C Reports 2003; 8:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/87\">",
"      Spahn DR, Kocian R. Artificial O2 carriers: status in 2005. Curr Pharm Des 2005; 11:4099.",
"     </a>",
"    </li>",
"    <li>",
"     Davis R. Blood substitute may be anticipated break. USA Today. June 20, 2000.",
"    </li>",
"    <li>",
"     Blood, sweat and hemoglobin: The long halting search for artificial blood takes some new twists. HeadsUp, Newsedge Corporation, Burlington, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/90\">",
"      Donahue LL, Shapira I, Shander A, et al. Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature. Transfusion 2010; 50:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/91\">",
"      Stowell C. Blood substitutes: time for a deep breath. Transfusion 2008; 48:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/92\">",
"      Estep T, Bucci E, Farmer M, et al. Basic science focus on blood substitutes: a summary of the NHLBI Division of Blood Diseases and Resources Working Group Workshop, March 1, 2006. Transfusion 2008; 48:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/93\">",
"      Kluger R. Red cell substitutes from hemoglobin--do we start all over again? Curr Opin Chem Biol 2010; 14:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/32/24073/abstract/94\">",
"      Olofsson CI, G&oacute;recki AZ, Dirksen R, et al. Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study. Anesthesiology 2011; 114:1048.",
"     </a>",
"    </li>",
"    <li>",
"     Safety Study of Hemospan&reg; in Prostatectomy Patients. file://clinicaltrials.gov/ct2/show/record/NCT00425334 (Accessed on May 08, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7923 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24073=[""].join("\n");
var outline_f23_32_24073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL PERSPECTIVE AND RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THE IDEAL OXYGEN CARRIER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hemoglobin-based oxygen carriers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Perfluorocarbons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FOCUS OF CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15033255\">",
"      Hemorrhagic shock of trauma and acute blood loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Animal experiments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Human studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Ethical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patients unable to receive red cell transfusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other potential uses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HBOC-associated side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Vasoactivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hemostasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Gastrointestinal side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Interference with laboratory assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Myocardial infarction and death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PFC-associated side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Regulation and licensure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Compassionate use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND FUTURE PROSPECTS FOR OXYGEN CARRIERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7923\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7923|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/40/10893\" title=\"table 1\">",
"      Oxygen carriers formerly under development",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=related_link\">",
"      Blood donor medical history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=related_link\">",
"      Inhaled nitric oxide in adults with pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=related_link\">",
"      Oxygen delivery and consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=related_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=related_link\">",
"      Red blood cell survival: Normal values and measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=related_link\">",
"      The approach to the patient who refuses blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=related_link\">",
"      Variant Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_32_24074="Erythrasma in axilla";
var content_f23_32_24074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80242%7EDERM%2F59529%7EDERM%2F51713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80242%7EDERM%2F59529%7EDERM%2F51713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 24-year-old male presented with erythematous plaques in the axillae. A Wood's lamp examination was positive for coral red fluorescence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Kosman Sadek Zikry, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 40-year-old diabetic male presented with red-brown patches in the axillae that resolved with erythromycin therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Jayakar Thomas, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical image of red-brown plaques of erythrasma in the groin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. John L. Aeling.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24074=[""].join("\n");
var outline_f23_32_24074=null;
var title_f23_32_24075="RTOG acute morbidity crit";
var content_f23_32_24075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The RTOG acute radiation morbidity scoring criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fully functional status (ie, able to work) with minor neurologic findings, no medication needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic findings present sufficient to require home care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nursing assistance may be required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications including steroids/anti-seizure agents may be required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic findings requiring hospitalization for initial management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serious neurologic impairment which includes paralysis, coma or seizures more than three times per week despite medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hospitalization required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade V",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any toxicity that causes death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: www.rtog.org/members/toxicity/acute.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24075=[""].join("\n");
var outline_f23_32_24075=null;
var title_f23_32_24076="ESC bridging therapy";
var content_f23_32_24076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology guideline summary: Bridging therapy in patients with mechanical valves who require interruption of warfarin therapy for noncardiac surgery or other procedure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Risk stratification for thromboembolism risk is essential. High risk is defined as one or more of the following; the risk increases with the number of risk factors present:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"1\">",
"       &bull; Risk factors for thromboembolism, especially if multiple. Risk factors include:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. Atrial fibrillation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. A prior history of thromboembolism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3. Heart failure or a left ventricular ejection fraction &le;30 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       4. A hypercoagulable state",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; A mechanical valve in the mitral position.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       &bull; Mechanical valves known to be associated with a high risk of valve thrombosis if the INR is low (Lillehei Kaster, Omniscience, Starr Edwards).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       &bull; Surgery for cancer or an infection, both of which can be associated with a hypercoagulable state.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       The following approach is recommended based upon risk stratification for both thromboembolism and the risk of bleeding, which varies with the site of surgery:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       &bull; For very high-risk patients, anticoagulation should not be interrupted if possible.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       &bull; Interruption of anticoagulation is not necessary for many minor surgical procedures, including dental extraction, and for procedures where bleeding can be easily controlled. In such patients, the INR should be lowered to a goal of 2.0 and surgical homeostasis should be meticulous.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       &bull; If anticoagulation must be interrupted:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. The patient should be admitted to the hospital and warfarin discontinued",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. Intravenous unfractionated heparin (goal aPTT 1.5 to 2.0) should be started as the INR gradually falls. The safety of subcutaneous low molecular weight heparin started at home has not been established.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3. Heparin and warfarin should be resumed as soon as possible after surgery; heparin is continued until the INR is within the goal therapeutic range.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Butchart EG, Gohlke-Barwolf C, Antunes MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005; 26:2463.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24076=[""].join("\n");
var outline_f23_32_24076=null;
var title_f23_32_24077="Survival after AVR";
var content_f23_32_24077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Long-term mortality in patients undergoing AVR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 262px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 2227 patients undergoing aortic valve replacement who survived the first postoperative month, the observed long-term mortality (open blue circles) is higher during the entire follow-up period when compared to that expected in the general population (closed red circles).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kvidal P, Bergstrom R, Horte LG, Stahle E. J Am Coll Cardiol 2000; 35:747.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24077=[""].join("\n");
var outline_f23_32_24077=null;
var title_f23_32_24078="LV mass LVEF outcome";
var content_f23_32_24078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Left ventricular mass is an independent predictor of mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 294px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the SOLVD trials of 1172 patients with left ventricular (LV) dysfunction, Kaplan-Meier survival curves demonstrate that increased LV mass &ge;298 g is an independent risk factor for all-cause mortality (p = 0.0014); a one standard deviation increase in LV mass is associated with a 17 percent increased risk of death. A LV ejection fraction (LVEF) &ge;35 percent, however, is protective in those with LV mass &ge;298 g.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Quinones MA, Greenberg BH, Kopelen HA, et al, for the SOLVD Investigators. J Am Coll Cardiol 2000; 35:1237.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24078=[""].join("\n");
var outline_f23_32_24078=null;
var title_f23_32_24079="Distal radius torus fx";
var content_f23_32_24079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Torus (or buckle) fracture of the distal radius",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Torus fractures of the distal radius. Torus fractures are caused by compressive forces that lead to buckling of the cortex (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rajvee Shah, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_32_24079=[""].join("\n");
var outline_f23_32_24079=null;
